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Abstract 
Collagen, the main component of bone extracellular matrix (ECM) represents a 
protein with a defined super-molecular organization. For stable fibril formation, the 
basic element of collagen, the fiber undergoes several intra- and extracellular 
modifications. One major process of collagen / matrix maturation is collagen cross-link 
formation. This process is tissue-specific, and involves a variety of cellular and matrix 
derived signals. Inhibition of lysyl oxidase (Lox), an enzymatic key player in cross-link 
formation, leads to improper collagen cross-linking and altered fibrillogenesis. In vitro 
and in vivo experiments confirmed that these aberrations in matrix formation are 
accompanied by loss of bone mineral, reduced bone strength and altered 
mineralization.  
A further factor involved in tissue development is regulation of gene 
expressions by epigenetic DNA methylation. To date, sparse research has been 
performed regarding the significance of this mechanism for bone development and 
pathogenesis. Therefore, in this thesis the role of epigenetic mechanisms in 
osteoblastic development was examined. 
By treatment of the murine pre-osteoblastic MC3T3-E1 cell line with two lysyl 
oxidase inhibitors, namely beta aminopropionitrile (bAPN) and homocysteine (hcys), 
we monitored and compared the effects of these two lathyrogens on the osteoblastic 
cells. The expression levels of osteoblastic genes were analyzed employing 
quantitative real time PCR (qPCR) and gene expression microarrays. Markers for 
osteoblastic activity and cell proliferation were analyzed by viability tests and alkaline 
phosphatase activity tests and effects on collagen cross-link formation were 
measured by FTIR. First results indicated that bAPN as well as hcys, besides the 
enzymatic inhibition down regulate the mRNA expression of Lox. Due to the greater 
clinical relevance of hcys, using ELISA, immuno blotting and chromatin immuno 
precipitation techniques we identified the cellular pathway responsible for the effect 
of hcys on the expression of Lox. This involves IL-6, the transcription factor FLI1 and 
the DNA methyltransferase DNMT1. DNA methylation analysis of the Lox promoter 
revealed that hcys suppresses Lox expression by DNA methylation.  
Finally, a new mechanism controlling ECM mediated proliferation and 
differentiation of osteoblasts was elucidated. By seeding MC3T3-E1 cells on collagen 
type I we observed an up-regulation of osteoblastic genes and a down regulation of 
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the pro-apoptotic gene Fas when compared to control. Using several inhibitors, 
qPCR and DNA methylation analysis we found that extra-cellular collagen type I via 
FAK, MAPK and the transcription factor AP1 directly up-regulates Dnmt1 which in 
turn maintains promoter methylation of the gene Fas thus repressing its expression.  
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Zusammenfassung 
Kollagen Typ I, der Hauptbestandteil der extrazellulären Matrix des Knochens, weist 
eine super-molekulare Organisation auf. Die einzelnen Kollagenmoleküle werden 
einer Reihe von intra- und extrazellulären Modifikationen unterzogen, die es ihnen 
ermöglicht extrazellulär Kollagenfibrillen auszubilden. Ein wesentlicher Schritt dabei 
ist die Ausbildung von Kollagenquervernetzungen. Dieser Prozess ist 
gewebespezifisch und wird von vielen zellulären und matrix-abhängigen Signalen 
gesteuert. Hemmung der Lysyloxidase (Lox), ein Schlüsselenzym der 
Kollagenvernetzung, führt zu veränderten Quervernetzungen und gestörter 
Fibrillogenese. Ergebnisse aus in-vitro als auch in-vivo durchgeführten Experimenten 
bestätigten, dass solche Veränderungen zu Knochenmineralverlust, reduzierter 
Knochenfestigkeit und einer veränderten Mineralisation führen.  
 Ein weiterer Faktor der eine wesentliche Rolle in der Organ und 
Gewebsentwicklung spielt ist die Regulierung der Expression von Genen durch 
epigenetische DNA-Methylierung. Bis zum jetzigen Zeitpunkt ist die Bedeutung von 
diesem Mechanismus in der Knochenentwicklung und Pathogenese nur wenig 
erforscht worden.  In dieser Dissertation wurde daher auf die Rolle epigenetischer 
Genregulationen im Osteoblasten intensiv eingegangen.  
 Nach Behandlung der pre-osteoblastären MC3T3-E1 Maus Zelllinie mit den 
zwei Inhibitoren der Lox, beta aminopropionitrile (bAPN) und Homocysteine (hcys), 
haben wir den Effekt von diesen zwei Lathyrogenen auf die Zelllinie analysiert und 
verglichen. Die Expression von osteoblastären Genen wurde mittels „real time 
polymerase chain reaction“ (qPCR) und „gene expression microarrays“ untersucht. 
Marker der osteoblastischen Aktivität und Zellproliferation wurden durch Messung 
der Aktivität der Alkalischen Phosphatase sowie Viabilitätstest bestimmt. Die Effekte 
der Substanzen auf die Kollagenquervernetzung wurden durch „Fourier-Transform-
Infrarot-Spektrometrie“ (FTIR) gemessen. 
Die ersten Ergebnisse zeigten dass sowohl bAPN als auch hcys Lox nicht nur 
enzymatisch hemmen sondern auch dessen mRNA Expression vermindern. Unter 
Berücksichtigung der  klinischen Bedeutung von hcys, haben wir den zellulären 
Signalweg für die hcys-abhängige Verminderung der Lox Expression erforscht. Dabei 
nutzten wir Techniken wie „Enzyme-linked immunosorbent assay“ (ELISA), Immuno 
Blotting und Chromatin-Immunopräzipitation (ChIP). Auswertungen ergaben das 
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Interleukin 6 (IL-6), der Transkriptionsfaktor „Friend leukemia integration 1“ (FLI1) 
und die DNA-Methyltransferse 1 (DNMT1) in der Repression von Lox durch hcys 
involviert sind. Untersuchungen an der Promotorregion des Lox-Gens ergaben eine 
DNA-methylierungsabhängige Regulation der Lox Expression durch hcys. 
Im letzten Teil der Arbeit wurde ein neuer Signal –Transduktionsweg 
aufgeklärt, durch den die extrazelluläre Matrix (ECM) die Proliferation und 
Differenzierung von Osteoblasten fördern kann. Beim Aussähen von MC3T3-E1 
Zellen auf mit Kollagen Typ I beschichtete Platten haben wir eine erhöhte Expression 
an osteoblastären Genen und eine verminderte Expression des pro-apoptotischen 
Gens Fas beobachtet. Durch die Verwendung verschiedener Inhibitoren, qPCR und 
DNA-Methylierungsanalysen konnten wir zeigen, dass das extrazelluläre Kollagen 
Typ I via FAK, MAPK und den Transkriptionsfaktor AP1 direkt die Expression des 
Gens Dnmt1 stimuliert was in weiterer Folge für die Stilllegung des Gens Fas durch 
epigenetischer DNA-Methylierung verantwortlich ist.  
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Abbreviations: 
ALP alkaline phosphatase activity 
bAPN β-aminopropionitrile 
ChIP chromatin immuno precipitation 
CpG cytosine-guanine di-nucleotide 
DMSO dimethly sulfoxid 
ECM extra cellular matrix 
ELISA enzyme-linked immunosorbent assay 
ERK extracellular-signal regulated kinase 
FTIR fourier transform infrared spectroscopy 
hcys homocysteine 
JAK2 janus kinase 2 
MAPK mitogen-activated protein kinase 
OI osteogensis imperfecta 
PBS phosphate buffered saline 
qPCR quantitative real-time polymerase chain reaction 
s.d. standard deviation 
 
Abbreviations of directly analyzed genes 
Bglap2 bone gamma-carboxyglutamate protein 2 (osteocalcin) 
Ccna2 cyclin A2 
c-Fos FBJ osteosarcoma oncogene 
c-Jun jun oncogene 
Col1a1 collagen, type I, alpha 1 
Dnmt1 DNA methyltransferase (cytosine-5) 1 
Dnmt3b DNA methyltransferase (cytosine-5) 3 
Fas Fas - TNF receptor superfamily member 6 
Fli1 friend leukemia integration 1 
Hells helicase, lymphoid specific 
IL-6 interleukine 6 
Lox lysyl oxidase 
Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 
Runx2 runt related transcription factor 2 
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1. Introduction 
1.1 Lathyrism, clinical manifestations, causes and mechanisms 
Lathyrism is one of the oldest neurotoxic diseases known in Man but the causes 
leading to this pathology were only recognized by the early twentieth century (1). 
Once prevalent throughout Europe, North Africa, Middle East and parts of the Far 
East, the disease is presently restricted to India, Bangladesh and Ethiopia (2). 
Lathyrism is a form of irreversible, non-progressive spastic paraparesis associated 
with pathological degenerations of connective tissues like bone or blood vessels (3, 
4). 
Initially, the disease appeared distinct between humans and animals and was 
diagnosed by degeneration of the nervous system associated with spastic 
paraplegia, pain and hypesthesias in Man (neurolathyrism) and by skeletal lesions 
like kyphoscoliosis, exostoses and lameness in animals (osteolathyrism, Fig. 1 and 
2). Later, a variety of skeletal lesions were also identified in Man: slipping of the 
upper femoral epiphysis and kyphoscoliosis as well as weakness and fragility of bone 
(1, 3, 4).   
Lathyrism results from excessive consumption of food compounds containing a 
chemical class carrying a nucleophilic amino-group as for example β-
aminopropionitrile (bAPN, for molecular structure see Fig. 3) (4). These compounds, 
known as lathyrogens, are mainly found in legumes such as chick peas and vetch, 
are derivatives of amino acids and 
act as metabolic antagonists of 
glutamic acid, a neurotransmitter in 
the brain (2, 4). Furthermore, 
lathyrogens were described to inhibit 
the enzymatic activity of the enzyme 
lysyl oxidase (LOX), a gene involved 
in the formation of cross-links 
between the collagen chains (5-7). 
The mechanism by which bAPN 
inhibits LOX activity is still unknown, 
other LOX inhibitors like ureides, 
semicarbazides and 
thiosemicarbazides are believed to 
Figure 1 Radiogram of a 13-week-old rat fed with a diet containing 
50 per cent Lathyrus odoratus peas from 4 weeks of age. Scoliosis, 
subluxation of the shoulders, thoracic deformity and bowing of the 
long bones are clearly observalble (1).  
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chelate the prosthetic Cu(II)-bipyridine 
cofactor complex in the enzyme (8). A 
recent work showed that bAPN clearly 
inhibited the formation of the two major 
bone collagen type I cross-links, pyr and 
dehydrodihydroxylysinonorleucine (deH-
DHLNL) (6). The work showed also that 
bAPN not only inhibits collagen cross-link 
formation but also influences the 
expressions of genes important for 
osteoblastic proliferation and differentiation. 
Thus, the mRNA expression of collagen 
type I alpha 1 (Col1a1) was increased and 
the mRNA expressions of osteocalcin (Bglap2) and of Lox was significantly 
decreased after bAPN treatment in murine pre-osteoblastic MC3T3-E1 cells (6). 
Thus, beside the enzymatic inhibition of LOX by bAPN, the decreased collagen-
cross-links after bAPN treatment may also be attributed to the suppressive effect of 
the lathyrogen on the mRNA expression of Lox showing a dual effect of the 
compound on osteoblasts development and bone strength. Furthermore, it was 
shown that culturing of MC3T3-E1 cells for 1 week on 
bAPN-marred ECM, still significantly increased Col1a1 
mRNA levels and significantly reduced Bglap2 mRNA levels 
when compared to cells seeded on untreated ECM (6). This 
indicates that even in absence of the lathyrogen, bAPN 
marred ECM still influences osteoblastic gene expressions 
suggesting the existence of feedback mechanisms between ECM and interacting 
osteoblast like cells regulating osteoblastic function and differentiation.  
 
 
1.2 Collagen cross-linking and folding in relevance to bone development 
Correct collagen folding and cross-linking is essential for the formation of an 
adequate extra cellular matrix (ECM) which guarantees stability, elasticity and 
maturation of various connective tissues of mesodermal and mesenchymal origin (9-
14). The organic part of bone’s ECM consists mainly of collagen type I triple helices 
Figure 3. Molecular structure of 
beta aminopropionitrile (Molecular 
weight: 256 g/mol)  
Figure 2. Sagittal section of the mid-thoracic vertebrae in 
a 56-day old rat fed a diet containing 0.2 per cent bAPN 
from 23 days of age. Slipping of one vertebra and 
loosening of the interspinous ligaments at the level of the 
slipping can be seen (1).  
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which are composed by two alpha 1 (COL1A1) polypeptide chains and one alpha 2 
(COL1A2) polypeptide chain. Each triple helix is firstly synthesized as pro-collagen 
and undergoes a variety of processing and modification steps, intra- as well as 
extracellularly (15). For post-translational collagen modifications at least 10 different 
enzymes are needed, whereby most of them being specific to collagens or proteins 
with collagenous sequences (16). During intracellular steps, specific lysyl and prolyl 
residues are hydroxylated as well as some hydroxylysines are glycosylated, collagen 
polypeptide chains are then assembled to pro-collagen triple-helix domains which are 
packed into saccules and secreted extracellularly via the Golgi complex (16, 17). 
Intracellular hydroxylation of prolines is necessary for the generation of stable triple-
helical domains. Lysyl-hydroxylations mediate specific cross-linking sources and 
constitute furthermore glycosylation sites which hinder staggering and lateral packing 
of collagen fibers within the cell (16). Extracellularly, the pro-collagen molecule is 
converted to collagen and incorporated into stable, cross-linked collagen fibrils (18, 
19). To assure this process, firstly C- and N-terminal pro-collagen peptides are 
removed from the collagen triple helix by procollagen C-proteinase (BMP1) and 
procollagen N-proteinase, respectively (15). The resulting tropocollagen molecules 
are incorporated into collagen fibrils which become stabilized by covalent cross-
linking between the individual collagen molecules. For extracellular collagen cross-
linking, oxidative deamination of ε-amino groups of lysine and hydroxylysine residues 
on the collagen triple helix by the enzyme LOX is necessary. This forms highly 
reactive aldehyde moieties which lead to the formation of covalent intra- and 
intermolecular cross-links among the helices by spontaneous condensation reactions 
(16). Six different collagen cross-links have been identified yet: 
histidinohydroxylysino-norleucine (HHL) dehydrohistidinohydroxy-merodesmosine 
(deH-HHMD), pyridinoline (pyr), deoxypyridinoline (d-pyr), pyrrole (prl), and 
deoxypyrrole (d-prl). Depending from tissue type, the cross-linking patterns and 
molecular distributions vary from tissue to tissue (20).  
 
1.3 ECM and osteoblastic differentiation 
Beside this physical attribute played in connective tissues, correct cross-linking and 
folding of fibrillar ECM components strongly influence cell differentiation of precursor 
cells by feedback mechanisms (9-11, 21). A functional collagenous bone matrix is 
critical for cell-cell and cell-matrix interactions; recently it was demonstrated that un-
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correct folding of collagen type I protein exposes cryptic binding sites regulating 
osteoblastic behavior during cell differentiation, tissue repair, and regeneration (11). 
Furthermore, studies suggested that beside the already known differentiation stimuli, 
the structural conformation of extracellular collagen I plays a crucial role in the 
differentiation of specific cell lineages (21-23). Pluripotent mesenchymal bone 
marrow stromal cells are an important source for tissue homeostasis and repair and 
have the potential to differentiate into diverse lineages like osteoblasts or adipocytes 
(24). Several works proposed that dependent on the structural state of the matrix, cell 
differentiation into specific lineages is specifically regulated through distinct signaling 
pathways. Thus, on native (triple-helix folded) collagen I matrices inefficient 
adipogenesis is observed, whereas on denatured (partially unfolded) collagen I 
matrices an efficient p38 kinase dependent adipogenesis is observed. To the 
contrary, on native collagen I matrix osteogenic differentiation occurs efficiently but 
not on the denatured counterpart. The osteogenic differentiation process was 
demonstrated to be mitogen-activated protein kinase 1 (MAPK1) and heat shock 
protein 90 (HSP90) dependent (25). The matrix conformation-mediated regulation of 
cell differentiation appears to be caused by differential cellular stress responses after 
exposure of the cells to the native or to the denatured collagen I matrices. The matrix 
mediated cellular stress responses are proposed to originate from the different matrix 
properties between native and denatured collagen-ECM to which the cells are 
exposed, namely matrix contractions and matrix tenseness. Integrin α2β1, a dimer of 
integrin alpha 2 (ITGA2) and beta 1 (ITGB1) was identified as stress-signal mediator 
between the by native collagen composed ECM and the MAPK1-dependent 
osteoblastic differentiation pathway (25). Thus, increases of HSP90 levels induce the 
expression and activation of integrin α2β1 which in turn activates the MAPK1-
signaling pathway hence facilitating osteogenesis and suppressing adipogenesis. 
The authors suggested that ECM mediated cellular stress responses might be 
frequently implicated in differentiation of several specific cell lineages as diverse 
factors involved in cellular stress response seem to activate differentiation of diverse 
cell lineages (21, 22, 25). Thus, it was shown that myogenesis of satellite stem cells 
is promoted by ECM mediated activation and nuclear translocation of Beta-catenin 
(CTNNB1), a stress response component which was shown to be essential for 
skeletal myogenesis (21, 26, 27). Further, activation of HSP70 may induce 
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chondrogenesis as HSP70 was demonstrated to stimulate of the chondrogenic 
transcription factor SOX9 (21).  
Clinically, beside lathyrism further pathological manifestations caused by disrupted 
collagen-folding or by inappropriate ECM formation affecting bone homeostasis are 
known. Osteogenesis imperfecta (OI) is a dominant genetic bone disorder resulting 
from defective connective tissue formation mostly caused by functional mutations of 
type I collagen genes (COL1A1 and COL1A2). These point mutations often substitute 
glycines with other residues (28, 29). For collagen triple-helix formation, the protein 
primary structure requires glycine residues at every third position as for assembly of 
the triple helix this residue at the interior of the helix-axis is indispensable because 
there is no space for a larger side group than glycine’s single hydrogen atom (15, 
18). Therefore, polymorphisms substituting this amino acid hinder a correct triple-
helix formation of the collagen fibril creating a bulge in the collagen complex, which in 
turn influences both, the formation of an adequate ECM as well as appropriate 
interactions between ECM and cellular networks. Depending on the type of OI, the 
severity of the symptoms varies from patient to patient and includes bone fragility, 
skeletal deformities, scoliosis, hearing loss and others (29). Genes that concern post-
translational modifications of type I collagen molecules such as cartilage-associated 
protein (CRTAP), leucine proline-enriched proteoglycan (LEPRE1), peptidylprolyl 
isomerase B (PPIB), serpin peptidase inhibitor, clade H (heat shock protein 47, 
SERPINH1) and FK506 binding protein 10 (FKBP10) were also found to be the 
causative candidates for OI (30). 
 
1.4 Molecular basics of osteoblastic differentiation 
Osteoblasts, the bone forming cells, derive from undifferentiated mesenchymal stem 
cells (31). The differentiation stages of osteoblasts were defined as osteoprogenitor 
cells, pre-osteoblasts, mature osteoblasts, osteocytes, and lining cells (32). 
Osteoprogenitor cells are committed cells which are induced to differentiate into 
preosteoblasts or osteoblasts by growth factors like the bone morphogenetic proteins 
(BMPs). Pre-osteoblasts are characterized by a high cell proliferation rate in 
concomitance with the expression of matrix forming collagens, Osteopontin (SPP1) 
and other genes (33-35). Mature osteoblasts express high levels of osteocalcin 
(OCN, BGLAP2) and mineralize the extra cellular matrix (33, 36). Osteocytes are 
housed in lacunae, they stabilize bone mineral and play a key role in homeostatic, 
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morphogenetic, and restructuring processes that regulate the mineral content and 
architecture of bone mass (37). Bone lining cells are inactive osteoblasts which cover 
the surface of most bones in an adult. Bone lining cells are suggested to regulate the 
transport of calcium and phosphate into and out of the bone (38). Although, the 
proposed schema suggests that an osteoblast moves through all differentiation 
stages, the co-existence of diverse functional sub-groups of osteoblasts is discussed 
(39, 40).  
Cell fate determination of bone marrow deriving mesenchymal stem cells (MSC) 
depends mainly on extra-cellular stimuli like growth factors, extra-cellular matrix and 
other microenvironmental factors (21, 22, 41, 42). These multi-potent cells are 
predisposed to differentiate into various tissue lineages including chondrocytes, 
adipocytes, muscle cells and osteoblasts. BMPs play thereby an important role (43, 
44). BMP2 for example, induces MSC to osteoblastic differentiation and inhibits 
myogenic cells to differentiate into myotubes (45). The runt-related transcription 
factor 2 (RUNX2), which is induced by bone morphogenetic proteins, play an 
essential role in osteoblastic commitment and differentiation (12) as well as in the 
formation of the mineralized skeleton during embryogenesis and regulates 
maturation of the osteoblastic phenotype (46); as a central factor it implements extra-
cellular signals from BMPs and Wnt-pathways thus promoting cellular phenotypic 
commitment and osteogenesis (47). Knock out of Runx2 in mice results in the 
inability to form a mineralized skeleton and in perinatal lethality (48, 49). Runx2 over 
expression represses the differentiation of other cellular phenotypes of mesenchymal 
origin, as for example the development of myoblasts or chondrocytes, by Runx2 
dependent suppression of the gene for myogenic differentiation (Myod1) and Sox9, 
respectively (47, 48). Generally, cell differentiation is accompanied by down 
regulation of cell proliferation. Thus, it was shown that forced expression of Runx2 in 
pre-osteoblasts suppresses their proliferation (44, 49). Furthermore, the cyclin 
dependent kinase inhibitors p21 (Cdkn1a) and p27 (Cdkn1b) were shown to be 
Runx2 target genes (50, 51) and inhibition of p53 (Trp53) was demonstrated to be a 
prerequisite for Runx2 activation and bone formation (52).  
At the early stages of osteoblastic differentiation RUNX2 controls the expression of 
many extracellular matrix proteins like COL1A1 (53), fibronectin (FN1) (53), bone 
sialoprotein-2 (IBSP), osteopontin (SPP1) (54) or osteocalcin (BGLAP2) (48, 54). As 
very recently shown, during the late phase of osteoblastic differentiation, Runx2 
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expression is down regulated by the zink finger protein 521 (Zfp521) which is 
suggested to permit complete osteoblastic differentiation as Runx2 over expression 
during this differentiation phase was shown to inhibit complete osteoblast maturation, 
thus provoking diverse bone pathologies in mice (55-58). Runx2 expression itself is 
regulated by diverse factors in osteoblasts. BMP4 and BMP7 induce its transcription, 
SATB2 directly interacts with it and enhances its activity whereby RUNX2 auto 
regulates its own expression by a negative feedback mechanism (47). The 
homeodomain proteins msh homeobox 2 (Msx2), distal-less homeobox (Dlx3) and 
Dlx5 represent a regulatory network for commitment of the bone cell phenotype. 
They are important regulators of osteoblastic differentiation in the adult skeleton 
whereby acting upstream, Msx2 repress Runx2, while Dlx3 and Dlx5 are potent 
activators of Runx2 and other bone related genes in osteoblastic lineage cells (47). 
Msx2 promotes commitment and early differentiation of osteoprogenitor cells and 
inhibits adipocyte differentiation. However, Msx2 hinders ossification of non-osseous 
cells and expression of genes of the mature osteoblastic phenotype (59-62). A further 
bone tissue specific transcription factor regulated by Runx2 which is also significantly 
involved in osteoblastic differentiation is osterix (Sp7). Similar to Runx2, Sp7 
depleted mice also lack bone tissue formation, although Runx2 is normally 
expressed. This suggests that both transcription factors are essential for normal bone 
development and cover distinct fields of action: Sp7 promotes proliferation of 
progenitor cells, while Runx2 regulates genes of the pre-osteoblastic/osteoblastic 
phenotype having an anti-proliferative effect (63, 64). 
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As summarized in figure 4, Runx2 plays a central role in bone development. Wnt 
pathways and BMP signaling regulate chondrogenesis as well as osteogenesis. The 
Wnt/ß-catenin pathway as well as Bmp2 activates Runx2 in MSCs. Bmp2 induces 
Dlx3 and Dlx5 which increase Bmp2 induced Runx2 expression. Furthermore, Bmp2 
induces Sp7 which is up regulated by Runx2. Dlx3, Dlx5 and Sp7 can also directly 
stimulate the expression of bone genes independently of Runx2. Further, Runx2 in 
concomitance with Smad1 and Smad5 functions as a hub for differentiation of a 
progenitor cell into the osteogenic lineage via integration of the Bmp2 signal (47).  
The biological functions of the dimeric transcription factor complex activator protein -
1 (AP-1) in skeletal development was clearly shown by several genetically modified 
mice and cells models. AP-1-components like Fos were demonstrated to be key 
players in osteoblastic and osteoclastic cell differentiation (65). Knock out of Fos in 
mice were shown to provoke osteopetrosis whereby the Fos trans-gene mice 
developed osteosarcomas (66) . The AP-1 complex can be formed by a great variety 
of proteins of the Fos, Jun, and activating transcription factor (ATF)-families and it is 
differentially composed during osteoblast differentiation (65). Thus, Fos and Jun 
proteins are highly expressed in precursor and pre-osteoblasts. However, during 
extracellular matrix production and mineralization their levels decline. In fully 
Figure 4. Signal pathways involved in mesenchymal stem cell differentiation. The role of Wnt signaling and BMP2 for 
osteoblastogenesis and chondrogenesis are shown. The central role played by Runx2 in osteoblastic differentiation is 
demonstrated (Figure adapted from 47).  
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Figure 5. One carbon metabolic cycle showing Homocystein metabolism (Figure adapted from 
68).  
differentiated osteoblasts FOSL2 and JUND represent the major components of the 
AP-1 complex (67). Several osteoblastic genes are known to be regulated by the AP-
1 transcription factor complex as for example Col1a1 (65). In summary, the AP-1 
complex was shown to regulate proliferation, differentiation, and apoptosis of 
osteoblasts and osteoclasts (62, 64). 
 
 
 
1.5 Homocysteine and bone homeostasis 
1.5.1 The role of homocysteine as cell metabolite 
In the last years, the non proteinogenic α-amino acid L-homocysteine (hcys, formula: 
HSCH2CH2CH(NH2)CO2H) is with increasing interest discussed to affect bone 
homeostasis as proposed to act as lathyrogen (6, 69). Hcys is a natural eukaryotic 
metabolite known to be involved in the one carbon metabolic cycle (Fig. 5). Here it 
co-regulates several physiological and pathological pathways. In the first step of this 
cycle, hcys becomes methylated by the vitamin B12 dependent enzyme methionine 
synthetase (MS) which results in the generation of methionine. Activation of 
methionine to S-adenosylmethionine (SAM) by the enzyme methionine 
adenosyltransferase leads to methylation of DNA, proteins, membrane phospholipids 
or 
neurotransmitters
. After transfer of 
the methyl group, 
SAM converts to 
S-adenosyl-
homocysteine 
(SAH) which via 
reversible 
hydrolysis by the 
enzyme SAH 
hydrolase re-
generates hcys 
completing the 
cycle (68).  
 20 
However, hcys has also been shown to interfere with the activity of the collagen 
cross-linker LOX (69), altering post-translational modifications and cross-linking of 
collagen.  
 
1.5.2 Homocysteine as metabolic risk factor 
Epidemiological studies have shown that elevated hcys serum levels (>10 µmol/L) 
represent a risk factor for several chronic disorders such as cardiovascular disease, 
atherosclerosis, chronic renal failure, diabetes or the metabolic syndrome (70, 71). 
Moreover, hyperhomocysteinemia is known to affect bone development and 
homeostasis (68-70). In this context, a correlation between plasma hcys levels and 
collagen cross-link ratio in forming trabecular surfaces in human bone was recently 
reported (72). Furthermore, recent clinical and epidemiological data reported a 
correlation between elevated blood hcys levels and bone fracture risk (73-76). 
Several factors can lead to hyperhomocysteinemia. Risk factors include chronic 
kidney diseases, cigarette smoking, hypothyroidism, specific malignant tumors as 
well as the intake of definite drugs (73-76). Genetic causes include polymorphisms in 
the genetic code of mediator enzymes involved in homocysteine metabolism (81, 82). 
Among these, the most investigated single nucleotide polymorphism (SNP) affects 
the enzyme methylenetetrahydrofolate-reductase (MTHFR) which catalyzes the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate thus 
providing methyl-groups to the enzyme MS for methionine generation from hcys. This 
mutation substitutes a cytosine with a thymine at base pair 677 on MTHFR’s mRNA, 
thus replacing an alanine with a valine at the protein level. The SNP is present in the 
homozygous state in 5-10% of the general Caucasian population and causes a 
thermolabile form of the enzyme with an approximately 70% reduced activity thus 
provoking an hcys accumulation (77) . Elevated hcys levels can also be caused by 
nutritional deficiencies in folate, vitamin B12 or vitamin B6 (78). As mentioned before, 
vitamin B12 and folate are directly involved in hcys’s methylation cycle; the vitamin 
B6 dependent enzyme cystathionine-beta-synthase (CBS) metabolizes in further 
metabolic steps hcys firstly to cystathionine and subsequently to the amino acid 
cysteine. As shown by Papandreu et al. (79), folate supplementation (5 mg oral 
folate, twice a week) for two months to hyperhomocysteinemic children significantly 
decreased total hcys serum levels. In a large polish study, an inverse association 
between vitamins B6, B12 as well as folate consumption and hcys concentration and 
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prevalence of hyperhomocysteinemia was observed (80). Another study correlated 
folic acid supplemented food intake with higher serum and red blood folate and 
vitamin B12 concentrations and lower hcys serum levels (81). Moreover, an 
association between vegetarian diet, plasma hcys levels and bone mineral density 
was found in Slovak women (82). In this study, several bone development markers, 
serum folate and vitamin B12 levels, plasma levels of total hcys as well as bone 
mineral density of the femoral neck, trochanter, total femur and lumbar spine were 
compared between 141 long-term ovo-lacto-vegetarian women and a control group 
of 131 women consuming a standard western diet. The results show that vegetarians 
have significantly higher hcys plasma levels while vitamin B12 levels are significantly 
lower in this group. However, no differences were observed in folate levels between 
the two groups. Furthermore, vegetarians show significantly lower bone mineral 
densities (BMD) at the trochanter and on the total femur. A strong correlation 
between homocysteine levels and the BMD of the femoral neck, of the trochanter and 
of the total femur was found in all subjects (87). Thus, low vitamin B12, folate or 
vitamin B6 serum levels in concomitance with high hcys serum levels may function 
as predictors for negative bone development and homeostasis. 
 
1.6 Regulation of gene expression by epigenetic DNA methylation and the role 
of homocysteine 
 
1.6.1 DNA methylation and homocysteine, the principles 
A new, interesting issue raised in the last years concerns the role of hcys in the 
modulation of epigenetic DNA methylation. As a metabolite hcys is directly involved 
in DNA methylation as it acts as methyl-group “carrier”. Therefore, numerous efforts 
have been done during the last years to understand the impact of supplementations 
or depletions of this compound as well as of folate, vitamin B12 and vitamin B6 on 
epigenetic regulation of gene expressions. In mammals, DNA methylation is 
mediated by DNA (cytosine-5-)-methyltransferases (Dnmts) (83). By now three active 
Dnmts are known. Dnmt1 is discussed to be responsible for maintaining of global 
DNA methylation, whereas specific methylation by this enzyme was recently 
demonstrated as well (84). Dnmt3a and Dnmt3b are related to specific de-novo DNA 
methylation and Dnmt3l was shown to support Dnmt3a and Dnmt3b methylation, but 
lacks itself methyl-transferase activity (83). The biological role of Dnmt2 is still 
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unknown in mammals. Hells (PASG, LSH), a gene involved in chromatin remodeling, 
was recently shown to associate with Dnmt1 and Dnmt3b enhancing DNA 
methylation (85). Dnmts’ mediated epigenetic DNA methylation is characterized by 
deoxycytidine methylation at position 5’ of the base, whereas neighboring 
deoxyguanosines are essential resulting in specific methylation at CG sites, also 
called CpG sites; thereby “p” represents the base-linking phosphodiester bond in 
DNA backbone (83). Dnmts are part of the transcriptional machinery protein complex 
thus methylating the CpG sites during DNA replication (86). Generally, DNA is highly 
methylated at CpG sites, especially in non-coding regions. To the contrary, CpG 
islands are normally largely un-methylated at CpG sites (83, 87). CpG islands are 
regions of ~ 300 to 3000 base pairs (bp) in length with CpG content greater than 
50%, and ratio of observed CpG‘s by expected CpG‘s of 0.6. CpG methylation mostly 
suppresses gene expression of specific genes inhibiting transcription factor binding 
on the affected promoters (82, 86). Several transcription factor binding sites contain 
CpG dinucleotides as for example the binding sites for the transcription factors 
activating protein 2 (AP-2, TFAP2A) or for the specificity protein 1 (Sp1). Thus, after 
cytosine methylation of such sites, binding of a specific transcription factor is reduced 
by the methyl-group itself or by block of the transcription factor binding site through 
binding of methyl-binding proteins (MeCP2, MBD1, MBD2 and MBD4) or with this 
proteins bound repressors at the methylated CpG site (88); the gene becomes 
epigenetically silenced. However, it was also shown that in some cases hindrance of 
repressor binding at methylated CpG sites induces the opposite effect (89). 
Methylation of a single or of a few CpG’s in a gene promoter were shown to be 
sufficient for gene silencing (90), in other cases a correlation between promoter CpG 
methylation and gene expression were described (91, 92). Binding of methyl binding 
proteins generally recruit histone deacetylases to the affected sites provoking a 
condensed chromatin structure. Thus, changes in DNA methylation pattern lead 
furthermore to changes of chromatin status and stability determining differentiation, 
pathogenesis and senescence of a cell (88, 93-95). Aberrant CpG methylation of 
gene promoters are related to several pathologies and several factors are known to 
influence methylation of DNA. Thus epigenetic research focuses on cancer 
development, cardiovascular diseases, mental health, stem cell research, cell and 
tissue development and differentiation, gene imprinting and the interactions between 
environment and epigenetic regulation of gene expression. Furthermore epigenetic 
 23 
research investigates silencing of transposons, retroviruses and imprinting of genes 
as CpG methylation is strongly involved in these mechanisms. 
 
1.6.2 Disruptions of the homocysteine metabolism affect DNA methylation 
patterns 
Studies in several cell cultures, animal models and humans show that high hcys 
levels affect DNA methylation patterns (101-103). However, despite intense 
research, due to apparently contradictory results, the impact of aberrant hcys, folate, 
vitamin B6 and vitamin B12 levels on global and specific DNA methylation remains 
still unclear. For example, it was demonstrated that during the earliest stages of 
bovine embryonic development, high hcys concentrations induce hypermethylation of 
genomic DNA and developmental retardation in bovine embryos (96). Further, 
genome-wide analysis of CpG dinucleotides methylation identified gene-specific CpG 
methylation patterns associated with cord blood plasma homocysteine concentration 
and birth weight centile in humans (97). Moreover, it was shown that dietary methyl 
supplementation of pregnant agouti mice with extra folic acid, vitamin B12, choline, 
and betaine alters the phenotype of their offspring via increased CpG methylation at 
the agouti gene locus (98). However, it was also shown that long-term administration 
of folate/methyl-deficient diet in Fisher 344 rats causes global DNA hypermethylation 
in brain tissue but at the same time these epigenetic changes are opposite in the liver 
of the same folate/methyl-deficient rats (99, 100). Therefore, it seems that aberrant 
levels of hcys, folate, vitamin B6 and vitamin B12 alter DNA methylation dependent 
by cell type, phenotype, tissue and developmental stage of the organism. 
Furthermore, in vivo DNA methylation may also be influenced by various other 
factors as for example by rate of cell growth or inflammation (101-104). 
Consequently, the effect of aberrant hcys levels on epigenetic alteration of gene 
expressions relevant to pathogenesis of diseases has to be evaluated cell, tissue, 
and developmental stage specifically. 
 
2. Aims and focuses of this PhD thesis 
In regard to the above illustrated research state and to the effects of bAPN and hcys 
in bone development and homeostasis, the following aims were set in this PhD 
thesis.  
First, to investigate and compare the effects of the lathyrogens bAPN and hcys on 
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osteoblastic collagen matrix formation by using the pre-osteoblastic MC3T3-E1 cell 
line. Thereby collagen cross-linking and expression of genes involved in osteoblastic 
differentiation, matrix formation and collagen cross-linking (lysyl oxidase, lysyl 
hydroxylase, collagen type I, and others) were assessed by FTIR and quantitative 
real time polymerase chain reaction (qPCR) as well as by genome wide expression 
(GeneChip) analysis, respectively. Moreover, feedback signals from the matrix to the 
matrix producing cells should be analyzed and characterized.  
According to the first results, which showed that additionally to hcys dependent LOX 
enzymatic inhibition, hcys represses Lox mRNA expression as well, as second goal 
the mechanism behind this observation was defined. To gain an overview of the 
effects of hcys on MC3T3-E1 cells, genome wide expression analysis of hcys treated 
osteoblasts were performed. A special focus was set on the investigation of putative 
intra-cellular pathways involved in the hcys dependent down regulation of Lox mRNA 
expression. To accomplish this aim, selected molecular methods including qPCR, 
immuno-blotting, molecular cloning, DNA methylation analysis, ELISA and chromatin 
immuno precipitation (ChIP) were used. 
Finally, interactions between collagen type I containing ECM and osteoblasts are 
known to significantly influence osteoblastic adhesion, proliferation and 
differentiation. Thus, using several inhibitors, qPCR, global and specific DNA 
methylation analysis, mechanisms involved in collagen type I mediated prevention of 
anoikis and induction of differentiation were analyzed in MC3T3-E1 cells.  
Summarizing, this PhD thesis aimed to analyze and compare the effects of hcys and 
bAPN on osteoblastic proliferation and differentiation with a special focus on collagen 
cross-link formation. Further, feedback mechanisms between ECM and osteoblasts 
were examined. Generally, possible epigenetic mechanisms involved in these 
processes were investigated. 
 
3. Results 
3.1. Differential effects of homocysteine and beta aminopropionitrile on pre-
osteoblastic MC3T3-E1 cells (105) 
Hcys, a metabolite of the methionine-folate metabolism, and bAPN, a model 
component of natural occurring lathyrogens, were compared in regard to their effect 
on collagen cross-linking and on their impact on the mRNA expression of several 
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osteoblastic genes. As mentioned before, osteoblast-synthesized collagen matrix 
regulates the differentiation of precursor cells into mature osteoblasts. The aim of this 
study was to investigate the effects of bAPN and hcys on collagen cross-links and 
gene expression at the mRNA level by FTIR and quantitative qPCR, respectively. We 
found that bAPN and hcys down-regulated cell multiplication. While bAPN also down-
regulated the metabolic activity of MC3T3-E1 cells, hcys down-regulated it by lower 
concentrations but up-regulated it by higher; both substances up-regulated alkaline 
phosphatase activity. The substances increased the ratio of pyr/divalent cross-links 
of collagen, and down-regulated mRNA expression of lysyl hydroxylase Plod2 and 
Lox, genes which play an important role in the formation of a stable matrix. 
Furthermore, we demonstrated that both substances stimulated the expression of the 
indispensable regulator of osteoblastic differentiation Runx2. However, analysis of 
genome wide mRNA expression suggests that hcys and bAPN have differential 
effects on genes involved in osteoblastic differentiation and phenotype regulation. 
The results indicate that although both bAPN and hcys affect collagen cross-link 
post-translational modifications in a similar manner as far as pyr and divalent cross-
links are concerned, they have differential effects on the monitored gene expression 
at the mRNA level, with hcys exerting a broader effect on the genome wide mRNA 
expression. 
 
3.2 Homocysteine suppresses the expression of the collagen cross-linker lysyl 
oxidase involving IL-6, Fli1 and epigenetic DNA-methylation (106) 
As recently shown, hcys influences the formation of a stable bone matrix not only 
directly through the inhibition of the collagen cross-linking enzyme LOX but also by 
repressing its mRNA expression (105). The aim of this study was to elucidate the 
mechanisms underlying the hcys dependent down regulation of Lox expression. By 
means of genome wide expression analysis, qPCR, immuno-blots, chromatin 
immuno precipitation, molecular cloning and ELISA we identified a hcys-dependent 
stimulation of Interleukin 6 (IL-6) and genes involved in IL-6/JAK2 (Janus kinase 2) 
dependent signal transduction pathways in pre-osteoblastic MC3T3-E1 cells. 
Moreover, up-regulation of genes essential for epigenetic DNA methylation (DNA 
(cytosine-5-)-methyltransferases (Dnmts) and lymphoid-specific Helicase (LSC, 
 26 
Hells) was observed. Further investigations demonstrated that hcys increased via IL-
6/JAK2 the expression of Fli1 (Friend leukemia virus integration 1), a transcription 
factor, which we found essential for IL-6 dependent Dnmt1 transcription. Analysis of 
CpG rich Lox proximal promoter revealed an increased CpG methylation status after 
treatment of the cells with hcys indicating an epigenetic cause for hcys dependent 
Lox repression. Inhibition of the IL-6/JAK2 pathway or of CpG-methylation reversed 
the repressive effect of hcys on Lox expression. In conclusion we demonstrated that 
hcys stimulates IL-6 synthesis in osteoblasts, which is known to affect bone 
metabolism via osteoclasts. Further, IL-6 stimulation results via JAK2, FLI1 and 
DNMT1 in down-regulation of LOX expression by epigenetic CpG methylation 
revealing a new mechanism negatively affecting bone matrix formation. 
 
3.3 Extra-cellular matrix suppresses expression of the apoptosis mediator Fas 
by epigenetic DNA methylation (107) 
The extracellular matrix (ECM) of bone consists mainly of collagen type I, which 
induces osteoblastic differentiation and prevents apoptosis. Fas induces apoptosis in 
cells improperly adhering to ECM. Recently, it was described that Fas expression is 
modulated by epigenetic DNA methylation. Mouse MC3T3-E1 pre-osteoblastic cells 
were cultured either on collagen coated or on uncoated culture dishes for control. 
mRNA was isolated and gene expression was analyzed by quantitative qPCR. 
Furthermore, we measured global and specific DNA methylation. Compared to 
controls, cells cultured on collagen-coated dishes increased the expression of Runx2 
and OCN indicating differentiation of pre-osteoblastic cells. Additionally, collagen up-
regulated cyclin-A2 and down-regulated Fas expression suggesting increased cell 
multiplication. Furthermore, the expression of Dnmt1 and Hells, key mediators of the 
DNA-methylation process, was increased. As a consequence, we demonstrate that 
global DNA methylation and specific methylation of the Fas promoter was higher in 
MC3T3-E1 cells cultured on collagen when compared to controls. Investigation of 
signal transduction pathways by mean of inhibitors suggests that focal adhesion 
kinase, MAP- and Jun-kinases and AP-1 are involved in this process. In summary, 
we demonstrate that ECM prevents activation of Fas by epigenetic DNA methylation. 
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Figure 6. MC3T3-E1 Cells 48h after seeding at 10.000 
cells/cm²  
4. Materials and Methods 
 
4.1 Cell line used and culture conditions 
In the here presented published articles, the clonal murine calvarial pre-osteoblastic 
MC3T3-E1 cell line was used (Fig 6). This cell line has been established from 
C57BL/6 mouse calvaria and was selected because of the high ALP activity in the 
differentiated state. MC3T3-E1 cells differentiate form a pre-osteoblastic phenotype 
into mature osteoblasts which form mineral deposits extra-cellularly (108). During this 
differentiation process expression of Bglap2 (osteocalcin) and its regulator Runx2, 
two well-known markers of osteoblastic differentiation, increases (35). MC3T3-E1 
cells secrete also high amounts of collagen type I which significantly influence their 
proliferation and differentiation.  
MC3T3-E1 cells were cultured in 
humidified air under 5% CO2 at 37°C in 
alpha-minimum essential medium (a-
MEM; Biochrom, Berlin, Germany) 
supplemented with 5% fetal calf serum 
(Biochrom), 50 µg/ml ascorbic acid 
(Sigma), and 10 µg/ml gentamycin 
(Sigma). For propagation, cells were 
sub-cultured twice a week using 0.001% 
pronase E (Roche) and 0.02% EDTA in Ca2+- and Mg2+-free phosphate-buffered 
saline (PBS) before achieving confluence. To prevent a potential phenotypic drift 
during repeated sub-cultures the cells were not used more than 4 weeks after 
thawing. For experiments the cells were seeded in culture dishes at the indicated 
densities with or without the indicated inhibitors or additives and cultured for the 
specified culture times with medium changes twice a week.  
 
4.2 MC3T3-E1 treatment with diverse compounds and inhibitors, culture plate 
and ECM preparation 
To study influence of the lathyrogens, MC3T3-E1 cells were seeded in culture dishes 
at a density of 20,000/cm² and cultured overnight. On the next day, the medium was 
changed and the cells were treated with or without bAPN (Sigma) or hcys (Sigma) for 
1 week to gain two to three cell layers (109). Medium was changed once during the 
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treatment time. Based on previous publications (6, 69), the concentrations of the 
substances were 0.1 mM, 0.4 mM, 1 mM, and 4 mM. For hcys an additional 
concentration of 10 mM was studied. Culture time for matrix production was 7 days 
because previous results demonstrate that during this period MC3T3-E1 cells 
produces about 2 to 3 cells layers embedded in collagen (109). Moreover, this makes 
the results of the present study directly comparable with our previous report 
concerning bAPN (6). 
To demonstrate effects of hcys on the JAK2-pathway and on DNA methylation, cells 
were seeded at 20,000 cells/cm2 and cultured overnight. On the next day medium 
was changed and cell treated with 0.108, 3.6 or 10.8 mM mM hcys for 3, 6 or 14 
days. To demonstrate the effect of hcys on the JAK2 pathway or on DNA-
methylation, cells were seeded and cultured with 3.6 mM hcys for 3 days; thereafter 
30 µM of the specific JAK2 inhibitor AG490 (Calbiochem) solved in DMSO (Sigma) or 
50 µM of the DNA methylation inhibitor zebularine (Sigma) solved in H2O were added 
to the medium for further 3 days. To test effects of recombinant mouse IL-6 protein 
(PeproTech,Great Britain) on the cells, they where cultured with increasing 
concentrations (3 to 30 ng/ml) for 36 and 48 hours. To demonstrate the IL-6 
dependent activation of the JAK2 pathway by hcys, cells were treated with 3.6 mM 
hcys for 3 days, thereafter 4 µg/ml IL-6 antibody (AB) (PeproTech, Great Britain) 
were added to the medium for further 3 days. 
To study epigenetic effects of collagen-I matrix on expression and promoter 
methylation of Fas (110), MC3T3-E1 cells were seeded in culture dishes coated with 
or without rat-tail collagen at a density of 2,000/cm² and cultured for 2, 4, 6 hours, 1, 
2, 4 and 8 days with medium changes twice a week. For collagen coating, culture 
dishes were incubated for 1 hour with a collagen solution of 5 µg/cm² rat tail collagen 
(BD Biosciences) in 0.02 N CH3COOH as suggested by the supplier. Cells cultured 
on collagen-coated dishes were confluent after 4–5 days while control cells needed 
6–7 days culture time for confluence. For ECM production, living cells were removed 
by treatment with 0.5 % sodium deoxycholate (DOC) in PBS leaving the ECM after 
being cultured for a total of 7 days (Fig 7). Therefore cells were firstly washed twice 
with PBS and then incubated with the DOC solution for 20 minutes at 4°C. After 
dissolving of the cells, ECM was carefully washed 4 times with PBS to remove traces 
of DOC. For reseeding experiments, fresh MC3T3-E1 cells were seeded on the 
prepared ECM at a density of 20,000/cm² and cultured for 1 week. Treatment with 
 29 
Figure 7. Extra cellular matrix of MC3T3-E1 cells 
after 1 week of culture. After cell culture cells were 
dissolved with 0.5% sodium deoxycholate and the 
inhibitors of signal transduction was performed 
with the focal adhesion kinase inhibitor (FAK) 
genistein (111) (10 µM, Sigma), the selective 
MAP-/ER-kinase inhibitor PD98059 (112) (10 
µM, Promega) and the AP-1 inhibitor resveratrol 
(113) (40 µM, Sigma). In these experiments, 
inhibitors were added to the cell suspensions 30 
minutes before seeding of the cells. Genistein 
and PD98059 were solved in DMSO as 1,000-
fold stock-solution to prevent influence on gene 
expression (Thaler, R et al. in preparation) and 
resveratrol was dissolved in ethanol. 
 
 
4.3 Cell multiplication, viability and alkaline phosphatase activity (ALP) 
To estimate effects of the lathyrogens on cell multiplication, cell viability and ALP-
activity, a major indicator for osteoblastic differentiation (114, 115), MC3T3-E1 cells 
were seeded at a density of 20,000/cm² and cultured overnight. 
On the next day, the medium was changed and the cells were treated with or without 
bAPN or hcys at various concentrations for 1 week. For determination of cell number 
(DNA amount employed as surrogate), cell layers were washed with PBS and frozen 
with 1 mM Tris–HCl buffer (pH 8.0) containing 0.1 mM EDTA. During thawing, 
Hoechst 33258 dye (Polysciences, Warrington, PA) was added (1 µg/ml) and, after 
an incubation of 15 minutes at room temperature, the fluorescence was measured 
(excitation 360, emission 465 nm). The amount of DNA was estimated using a 
standard curve prepared from calf thymus DNA (Roche). Thereafter, alkaline 
phosphatase (ALP) activity was measured with p-nitrophenylphosphate (2.5 mg/ml in 
0.1 M diethanolamine buffer [pH 10.5], 150 mM NaCl, 2 mM MgCl2) by incubation of 
the cell layers for 15 minutes at room temperature. Absorption was measured in a 
microplate reader at 405/490 nm. ALP activity (units per milligram DNA) was 
estimated using a standard curve prepared from calf intestinal ALP (Roche). To 
assess cell viability, a commercially available assay (EZ4U; Biomedica, Vienna, 
Austria) was used, according to the protocol of the supplier.  
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4.4 Nucleic acid isolation 
RNA isolation 
RNA isolation was performed with the spin column format “SV Total RNA Isolation 
System Kit” (Promega) or similar RNA extraction Kits from other suppliers following 
manufactures instructions. In brief, firstly up to 1 x 106 cells were lysed in 175 µl of 
RNA lysis buffer and lysate was expelled into a 1.5 ml tube. Then, 350 µl of RNA 
dilution buffer was added to the lysate and heated on in a thermo block at 70°C for 3 
minutes. Afterwards, the solution was centrifuged at 13,000 × g for 10 minutes at 
room temperature and the cleared lysate solution was transferred to a fresh 
microcentrifuge tube by pipetting avoiding disturbing the pelleted debris. 200µl 95% 
ethanol were added to the cleared lysate, and mixed by pipetting. The mixture was 
then transferred to a spin column assembly and centrifuged at 13,000 × g for one 
minute. After centrifugation, nucleic acids were bound to the silica matrix of the spin 
basket; the liquid in the collection tube was discarded. For first purification, 600 µl of 
RNA wash solution was added to the spin column assembly and centrifuged at 
13,000 × g for 1 minute. Subsequently 50 µl of freshly prepared DNase solution was 
directly added to the membrane inside the spin basket and incubated for 15 min for 
DNA digestion. After this incubation, 200 µl of DNase stop solution was added to the 
spin basket, and centrifuged at 13,000 × g for 1 minute. Next, the spin column was 
washed with 600 µl RNA wash solution and centrifuged at 13,000 × g for 1 minute. 
Finally, the spin basket was transferred to a 1.5 ml elution tube and RNA was eluted 
with 100 µl of nuclease-free water by centrifugation at 13,000 × g for 1 minute. 
Purified RNA was stored at –80°C or subjected to cDNA  synthesis. 
 
DNA isolation 
For specific CpG methylation analyses, DNA was isolated with the DNeasy Blood & 
Tissue Kit (Qiagen) or with comparable DNA extraction kits following manufacturer’s 
instructions. In brief, a maximum of 5 x 106 cells were collected in 200 µl PBS in a 1.5 
ml tube and 20 µl proteinase K were added. Next 200 µl Buffer AL were added and 
solution was mixed thoroughly by vortexing and incubated at 56°C for 10 minutes. 
Afterwards, 200 µl ethanol (96%) were pipetted to the sample, mixture was 
transferred to a DNeasy mini spin column assembly and centrifuged at 6000 x g for 1 
min. DNA was bound to the collection basket and flow-through was discarded. 
Subsequently, 500 µl buffer AW1 was added to the spin column and centrifuged for 1 
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minute at 6000 x g. Then, 500 µl buffer AW2 was added spin column assembly was 
centrifuged for 3 min at 20,000 x g. Finally collection basket was placed into a 1.5 ml 
tube and DNA was eluted with 200 µl buffer AE by incubation at room temperature 
for 1 minute followed by centrifugation for 1 min at 6000 x g. RNA concentrations 
were measured spectroscopically at 260/280 nm. 
 
4.5 cDNA synthesis 
cDNA was synthesized from about 0.5 µg RNA using the Transcriptor 1st Strand 
cDNA Synthesis Kit (Roche) as described by the supplier (Roche). Thus, following 
components were mixed in a 1.5 ml tube (table 1): 
 
Component Volume Final conc.  
Total RNA  X 0.5 µg 
Random hexamer primer, 600 pmol/µl 2 µl 60 µM 
Water, PCR-grade X  
Total volume  13 µl  
 
Afterward, the template-primer mix was denatured by heating the tube for 10 min at 
65°C in a thermal block. Then tube was immediately cooled on ice. Subsequently the 
following components were added to the reaction mixture (table 2): 
 
 
 
Reaction vial was incubated for 10 minutes at 25°C followed by 60 min at 50°C. 
Reverse transcriptase reaction was stopped by heating the vial to 85° for 5 min 
followed by placing the tube on ice. cDNA was stored at -20°C. 
 
4.6 Measurement of gene expressions 
Changes in gene expressions were measured with two techniques. Genome wide 
effects on gene expressions were measured with Affymetrix GeneChip. Quality 
Component Volume Final conc.  
Transcriptor Reverse Transcriptase 
Reaction Buffer, 5× conc.  4 µl 1×(8 mM MgCl2) 
Protector RNase Inhibitor, 40 U/µl 0.5 µl 20 U 
Deoxynucleotide Mix, 10 mM each 2 µl 1 mM each 
Transcriptor Reverse Transcriptase, 20 
U/µl 
0.5 µl 10 U 
Final volume  20 µl  
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Figure 8. Principles of Sybr Green and TaqMan qPCR  
control of the RNA's as well as labeling, hybridization, and scanning of the hybridized 
arrays was performed by the Kompetenzzentrum fuer Fluoreszente Bioanalytik (KFB) 
(Regensburg, Germany) using the “mouse 430 2.0 chip” (Affymetrix). Changes in 
gene expression levels were shown as fold change in expression level in relation to 
the untreated cultures. 
To confirm the effects on the expressions of the principal genes analyzed, gene 
expression measurements by quantitative real-time polymerase chain reaction (qRT- 
PCR) were performed. Thereby, real-time quantization was measured by TaqMan as 
well as by Sybr-Green technique. In brief, real time gene expression quantization by 
Sybr-Green technique measures the increasing fluorescence generated by the 
intercalation of the asymmetrical 
cyanine dye Sybr-Green into the 
amplifying target gene as shown in fig 
8. The DNA-dye-complex absorbs 
blue light (λmax = 494 nm) and emits 
green light (λmax = 522 nm). For 
quantification of gene expression by 
TaqMan technique, additional to the 
sense and anti-sense primer, a third 
probe dual labeled with a fluorescent 
dye and a suitable quencher is used. 
This probe is usually designed to bind 
3’ next to the sense primer. As long 
as this labeled probe remains un-
cleaved, no fluorescent signal will be 
generated because prevented by the 
quencher on the probe. After binding 
of primers and labeled probe on the 
target sequence, during synthesis of 
the DNA, the 5´–3´ exonuclease 
activity of the Taq polymerase digests 
the dual-labeled probe disclosing the 
fluorescent signal as shown in fig 9. This permits quantitative measurements of the 
accumulation of the product during the exponential stages of the qPCR. The Sybr-
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Green primers and reference numbers for the FAM-fluorescent dye (emission λmax 
520 nm) labeled TaqMan primers (all predesigned by Applied Biosystems) used for 
gene expression analysis in the here presented publications are summarized in table 
3. For Sybr-Green qPCR, cDNA was amplified with FastStart Sybr-Green Master Mix 
(Roche) using the following cycling conditions: 10 minutes of initial denaturation at 
95°C followed by 45 cycles consisting of 30 seconds  denaturation at 95°C, 30 
seconds annealing at primer specific temperatures and extension at 72°C. For 
TaqMan qPCR, cDNA was amplified with the TaqMan Gene expression Master Mix 
(Applied Biosystems) with an initial denaturation step at 95°C for 10 minutes followed 
by 45 cycles alternating 60°C and 90°C. For gene ex pression normalization, we 
usually used an 18 S RNA TaqMan probe or alternatively a Gapdh TaqMan Probe 
(both Applied Biosystems, VIC-fluorescent dye labeled, emission λmax 550 nm) as 
indicated in the publications, all in combination with TaqMan Gene expression Master 
Mix (Applied Biosystems) at the indicated TaqMan cycling conditions. All qPCRs 
were performed in triplicate using the Corbett Rotor Gene 6000 real-time PCR cycler 
and expression was evaluated using the comparative quantitation method (116). For 
each experiment, the triplicate results of the qPCR were averaged and this mean 
value was treated as a single statistical unit. The data of the experimental results 
were presented as means ± standard deviation (s.d.). 
 
 
 
 
Sybr Green primers 
Gene  Forward primer (5’–3’) Reverse primer (5’–3’) Tm (°C)  
Dnmt1 
ACCGCTTCTACTTCCTCGAGGC
CTA 
GTTGCAGTCCTCTGTGAACACTGTG
G 
62 
Dnmt3b GGAGAAAGCCAGGGT AAGAGGGGGTGGAAGGA 63 
Hells TGAGGATGAAAGCTCTTCCACT ACATTTCCGAACTGGGTCAAAA 62 
Fas TATCAAGGAGGCCCATTTTGC TGTTTCCACTTCTAAACCATGCT 64 
Ccna2 ACATTCACACGTACCTTAGGGA CATAGCAGCCGTGCCTACA 62 
c-Fos CGGGTTTCAACGCCGACTA TTGGCACTAGAGACGGACAGA 63 
c-Jun CCTTCTACGACGATGCCCTC GGTTCAAGGTCATGCTCTGTTT 63 
Fli1 ATGGACGGGACTATTAAGGAGG  GAAGCAGTCATATCTGCCTTGG 62 
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Table 3. Primers and reference numbers of primers used for qPCR  
TaqMan probe sets (Applied Biosystems) 
Gene Reference number Fluore  Dye 
Tm 
(°C)  
Plod2 Mm00478767_m1  FAM 60 
Bglap2 X04142-EX2 FAM 60 
Lox Mm00495386_m1 FAM 60 
Runx2 Mm00501578_m1 FAM 60 
18sRNA Hs4319413E VIC 60 
Gapdh Mm4352339E VIC 60 
 
 
 
4.7 Measurement of protein expression by immunoblot technique 
Protein expression of genes regulated by hcys (106) was analyzed by immuno-
bloting. For protein extraction, after cell culture, MC3T3-E1 cell layers were washed 2 
times with cold (+4°C) PBS and scraped in SDS-sample b uffer (2% SDS, 100 mM ß-
mercaptoethanol, 125 mM Tris-HCl, pH 6.8) and heated at 95° for 5 minutes. 30 µg 
protein-extracts were fractionated on 8% or 10% SDS-PAGE depending on 
molecular weight of the proteins analyzed. Following SDS-gel electrophoresis, the 
proteins were transferred to nitrocellulose filters (Millipore) and blocked overnight 
with 10% blocking reagent (Roche) in TN Buffer (50 mM Tris, 125 mM NaCl, pH 8). 
Subsequently, the filters were incubated for 1 hour at room temperature with specific 
antibodies against the proteins to analyze (FLI1 (ref# C19), HELLS, (Lsh, ref# H-
240), LOX (ref# H-140), DNMT1 (ref# K-18), all purchased from Santa Cruz 
Biotechnologies, CA)) diluted 1:200 in blocking buffer. Afterwards, all filters were 
washed three times with immuno-blot wash buffer (TN buffer containing 0.01% 
Tween) and the FLI1-, HELLS- and LOX-blots were incubated for one further hour 
with an anti-mouse IgG/ anti-rabbit IgG horseradish peroxidase (HRP) labeled 
secondary antibody (Roche) diluted 1:20,000 in blocking buffer. The DNMT1-blot was 
incubated for one hour with an anti-goat IgG HRP labeled secondary antibody 
(Sigma) diluted 1:160,000 in blocking buffer. Finally, the blots were washed again 
three times with immuno-blot washing buffer before detection of light emission with 
the BM Chemiluminescence Western Blotting Kit (Roche) as described by the 
supplier. Chemiluminescence was measured with an image acquisition system 
(Vilber Lourmat, France). 
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4.8 Measurement of protein expression by enzyme-linked immunosorbent 
assay (ELISA) 
As gene expression measurements by qPCR indicated an hcys dependent up-
regulation of interleukin-6 (IL-6) mRNA expression in MC3T3-E1 cells, IL-6 protein 
expressions were measured by ELISA assay. For this purpose, MC3T3-E1 cells were 
seeded in triplicate and treated with or without increasing hcys concentrations (0.108 
mM, 1,08 mM, 3.6 mM) for 3, 6 and 14 days; culture medium was changed twice a 
week. After the corresponding hcys treatment, 1 ml of culture supernatant was saved 
and stored at -80°C. For IL-6 quantification, 96 we ll ELISA plates (Iwaki) were 
prepared by using the Murine IL-6 ELISA Development Kit as described by the 
supplier (PeproTech). In brief, Capture antibody was diluted in PBS to a 
concentration of 2 µg/ml and 100 µl were added to an ELSIA plate well (IWAKI) and 
incubated at room temperature overnight. Next day, liquid was removed and plate 
was washed three times with wash buffer (0.05% Tween-20 in PBS). Subsequently 
the wells were blocked with 300 µl blocking buffer (1%BSA in PBS) for 2 hours 
followed by plate wash. For IL-6 protein quantization, IL-6 standard was diluted from 
6 ng/ml to zero in diluent (0.05% Tween-20, 0.1% BSA in PBS) and 100 µl of each 
concentration or of sample were added in triplicate to the ELISA plate. The plate was 
incubated 2 hours at room temperature. Afterwards liquid was removed and plate 
was washed four times with wash buffer. Next, avidin-HRP conjugate was diluted 
1:2,000 in diluent, 100 µl were added per well and incubated at room temperature for 
30 minutes. Finally, IL-6 concentration was monitored by color development of ABTS 
liquid substrate (Sigma, 100 µl/well) with an ELISA plate reader (Glomax, Promega) 
at 405 nm with wavelength correction set at 650 nm. Every cultured well was 
measured in triplicate, these triplicate results were averaged and the mean value was 
treated as a single statistical unit. The complete experiment was performed twice. 
 
4.9 Analysis of specific DNA methylation 
To determine specific promoter methylation of Lox and Fas (106, 107) in MC3T3-E1 
cells, appropriate promoter fragments were generated by digestion of 1 µg of 
genomic DNA with 40 U of the CpG-methylation insensitive restriction enzyme MboII 
(New England Biolabs) for 20 minutes. Subsequently, the enzyme was heat 
inactivated at 65°C for 20 minutes. The promoter re gions were selected according to 
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Figure 9. Schematic representation of Lox (A) and Fas (B) promoters and first exons. Untranslated regions are represented as 
open boxes and coding regions as black arrows. The vertical bars above the horizontal line of the genes indicate the CpGs in the 
region. The Mbo II restriction sites are indicated with M and the numbers below the geneline denote the distance to the 
transcription start (TS) 
 
literature (110) or/and depending by CpG content. After MboII digestion, DNA was 
purified using a commercially available PCR clean-up Kit (Promega) following the 
supplier’s instructions. In the next step methylated DNA fragments were captured 
with the ‘‘MetylMiner Methylated DNA Enrichment Kit’’ (Invitrogen) following the 
supplier’s instructions. In brief, methylated DNA was captured by methyl blinding 
protein 2 (MBD2) coupled to magnetic beads and subsequently separated from the 
unmethylated DNA fraction. Methylated DNA was eluted from the MBD2-beads with 
200 µl of 2 M NaCl solution as single fraction independent from the CpG methylation 
density and concentrated by ethanol precipitation. Finally, the mean methylation 
status of the fragments was determined by amplifying the fragments by qPCR. 
Amplification ratios of the bound (methylated) DNA fraction to unbound 
(unmethylated) DNA fraction were calculated (for primer design see Table 4). 
Specific promoter configurations and CpG allocations are accurately described in the 
publications presented. 
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Table 4. Primers used for assessment of Fas and Lox promoter methylation status 
Gene Forward primer (5’–3’) Reverse primer (5’–3’) Tm (°C)  
Fas 
fragment 1 
CATACCCACAGGCAGTCTAGA CAGCCCAGAGTAACTCACTTC 62 
Fas 
fragment 2 
GAAGTAGAAACAGAAGCTGAG TTGCTACATCCCAACTGTAAC 62 
Lox promo-
ter/first exon 
GCATGTTCGGCCCAGATTAAGT
CG 
CAGAGTCTGGAGTAGAAGGAGGAG
G 
65 
 
 
4.10 Analysis of global DNA methylation 
For determination of global methylation of DNA in dependence of collagen type I 
(107), a recently published assay was used, which bases upon sensitivity of the 
HpaII restriction enzyme to methylated CpGs compared to the insensitivity of MspI to 
cut such restriction sites. To this end, 100 ng DNA was digested in multi core buffer 
(Promega) with 5 U MspI or HpaII or incubated without restriction enzyme 
(background) for 3 hours at 37°C in a total volume of 30 µl. The restriction of the DNA 
was followed by an end-fill reaction where to the restriction digest 20 µl of a mixture 
containing 0.1 µM Biotin-11-dCTP and 0.1 µM Biotin-11-dGTP (Perkin Elmer, Boston, 
MA) and 0.5 U Klenow-fragment of DNA-polymerase III (Promega) in 500 mM Tris–
HCl, pH 7.2, 100 mM MgSO4 and 1 mM dithiothreitol were added and incubated at 
room temperature for half an hour. Thereafter, the reaction was transferred into multi-
well plates (Optiplate, Beckman) and 100 µl of Reacti-BindTM DNA Coating Solution 
(Pierce, Rockford, IL) was added to each well and incubated overnight at room 
temperature. On the next day, the wells were washed once with TBS (10 mM Tris–
HCl pH 8.0, 150 mM NaCl). After a blocking step with 1% blocking solution (Roche) 
in TBS for 1 hour, a solution of 50 ng/µl streptavidin HRP-conjugate (Promega) in 
TBS was added and incubated for one further hour at room temperature. Thereafter, 
the wells were washed three times with TBS containing 0.5% Tween 20 and two 
times with water. 100 µl of the chemo-luminescence substrate was added to each 
well and the light emission was measured in a top-counter (Packard Instruments). 
Evaluation of DNA global methylation level of each biological sample was performed 
by forming the ratio between the signals given by the HpaII restriction (un-methylated 
CpGs) to the MspI restrictions (total CpGs).  
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Figure 10. Schematic representation of Dnmt1 promoter with first exon. Untranslated regions are represented as open 
boxes and coding regions as black arrows. Primers used for ChIP assay are represented as thin black arrows and Fli1 
binding sites as grey boxes. 
 
4.11 Determination of specific transcription factor binding by chromatin 
immuno-precipitation (ChIP) 
ChIP assays are used to evaluate the association of proteins (mostly transcription 
factors) with specific DNA regions. The technique involves cross-linking of proteins 
with DNA, fragmentation and preparation of soluble chromatin followed by immuno-
precipitation with an antibody recognizing the protein of interest. The segment of the 
genome associated with the protein is then identified by qPCR amplification of the 
DNA in the immuno-precipitates. To demonstrate binding of FLI1 transcription factor 
to Dnmt1 promoter (106), this technique was chosen by using the ChampionChip 
One-Day Kit (SABiosciences, MD) following manufacturer’s instructions. In brief, for 
this purpose, after MC3T3-E1 cell culture, medium was aspirated from the dish and 
10 ml of fresh fixing Buffer (1% formaldehyde in PBS) was added to the dish and 
cells were incubated at 37°C for 10 minutes. After f ixation cells were washed twice 
with ice cold PBS, harvested in 1.5 ml PBS and pelleted by centrifugation (800 x g for 
10 minutes at 4°C). Afterwards, cells were lysed wit h a lysis buffer and chromatin 
was sonicated with 3 rounds at 0.5 W for 8 s on, 10 s off, 5 times per round. 
Subsequently, the debris was pelleted by centrifugation (14,000 x g for 10 min at 4 
°C) and supernatant (shared chromatin) was transfer red to a 2 ml tube. Chromatin 
was incubated overnight on a rotor at 4°C with 4 µg anti-FLI1 antibody (ref# C-19, 
Santa Cruz, CA) or with 4 µg non-immune serum as negative control. Before 
immunoprecipitation 1% (10 µl) of the chromatin was saved and stored at 4°C for  
further use as reference. After immuno-precipitation of chromatin, antibody-bound 
DNA was extracted by protein beads, next protein was digested with proteinase K, 
DNA was washed and isolated. For quantization, enriched Dnmt1 promoter 
fragments which included 3 FLI1 binding sites (Fig. 10) were quantified by qPCR with 
the primers: forward (5’ - 3’) CTTCCCCCACTCTCTTGC, reverse (5’ – 3’) 
GAACAGCTCTGAACGAGAC. DNA signal of the FLI1 precipitated chromatin was 
normalized to the un-precipitated chromatin. 
 
 
 
 
4.12 Fourier transform infrared spectroscopy (FTIR) imaging 
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Spectroscopic analysis by FTIR Imaging Analysis was used for determination of 
pyr/divalent collagen cross-link ratio in MC3T3-E1 cell cultures after 7 days hcys 
treatment in the first work here presented. Therefore, after cell culture, medium was 
removed and cells/ECM were fixed in alcohol, scraped off the culture dishes, and 
transferred onto barium fluoride windows, where they were air dried. Following this, 
spectra were obtained in transmission with a Bruker (Germany) Equinox 55 
spectrometer coupled to a Bruker Hyperion 3000 FTIR microscope equipped with a 
motorized stage (±1 µm) and a 15× objective. The spectra were baseline-corrected in 
the amide I and II spectral area (~1500–1700 cm−1); water vapor was subtracted 
and then subjected to second derivative spectroscopy and curve fitting routines as 
described elsewhere (117). The collagen cross-link ratio was determined as 
previously described (117). 
 
4.13 Measurement of Dnmt1 promoter activity 
For localization of hcys’s/IL-6’s reactive sites on Dnmt1 promoter (106), several 
lengths and mutant forms of the promoter were cloned into the secreted alkaline 
phosphatase 2 (SEAP2) reporter vector (Clontech). More precisely, four fragments of 
the mouse Dnmt1 promoter were firstly cloned from MC3T3-E1 genomic DNA into 
the pGEM T-easy Vector (Promega) by using the following 5’-primers elongated to 
contain a BglII restriction site (underlined): TCGAGATCTGCCTTCGGGC-
ATAGCATGGTC for a 220 bp fragment carrying three putative FLI1 binding sites (as 
suggested in (118), at -30 bp, at -60 bp and at -96 bp from the somatic transcriptional 
start site (103), TCGAGATCTGCCTGTGTGGTACATGCTGC for the 190 bp 
fragment carrying two putative FLI1 binding sites (at -30 bp and at -60 bp), 
TCGAGATCTGGCCGCCCCCTCCCAATTGG for the 160 bp fragment carrying one 
putative FLI1 binding site (at -30 bp), 
TCGAGATCTGCGAAAAAGCCGGGGTCTCGTTC for the 150 bp fragment carrying 
no FLI1 binding sites. As 3’-primer we used 
GCCTGCGGACATGGTCCGGGAGCGAGCCTG. These fragments were 
subsequently cloned into the SEAP2 reporter vector by using BglII and EcoRI 
restriction enzymes. To generate mutated Dnmt1-SEAP2 fragments, the following 
primers with modified, putative FLI1 binding sites were designed (mutation sites form 
5´-TTCC to TTAA are in italics and underlined): 5´ CGGGCATAGCATGGTCTT 
AACCCACTCTCTTGCCCTG and complementary 3` CAGGGCAAGAGAGTGGGTT-
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Table 5. Sequence references 
AAGACCATGCTATGCCCG for the putative Fli1 binding site at -96 bp from the 
somatic transcriptional start site, 5` GTGGTACATGCTGCTTAAGCTTGCGCCG-
CCCC and complementary 3´ GGGGCGGCGCAAGCTTAAGCAGCATGTACCAC for 
the putative FLI1 binding site at -60 bp from the somatic transcriptional start site and 
5´ CTCCAAATTGGTTTAAGCGCGCGCGAA AAAGCCG and 3` CGGCTTTTTCG-
CGCGCGCTTAAACCAATTGGGAG for the putative FLI1 binding site at -30 bp from 
the somatic transcriptional start site. For transfection experiments with the various 
Dnmt1-SEAP2 vectors, SEAP2-control vector and the SEAP2-basic vector, MC3T3-
E1 cells were seeded at 20.000 cells/cm² in 48 multiwell plates. Six hours after 
seeding, cells were transfected with 0.15 µg/cm² vector construct using 1 µg/cm² 
DOSPER transfection reagent (Roche) following the suppliers protocol. After two 
days, cells were treated for further 3 days with 30 ng/ml of murine IL-6 (PeproTech) 
and finally, SEAP2-activity was measured in 50 µl culture supernatant using the 
SEAP2 bio-luminescence Kit (Roche) following suppliers instructions. Each 
experiment was run in biological quadruplicates and was repeated at least twice. 
 
 
4.14 Reference numbers of the used gene sequences 
 
Ref-number Organism Gene 
NM_010234 Mus musculus cFos 
NM_010591 Mus musculus cJun 
CH466522 Mus musculus Dnmt1 
CH466623 Mus musculus Dnmt3a 
NT_039207 Mus musculus Dnmt3b 
CH466534 Mus musculus Fas 
CH466522 Mus musculus Fli1 
CH466534  Mus musculus Hells 
CH466528 Mus musculus Lox 
 
 
 
4.15 Statistical analysis 
Statistical analyses were performed using either ANOVA or Student’s t-test using 
Prism 4.03 software (GraphPad Software, San Diego, CA). P ≤ 0.05 was considered 
as significant. All experiments were performed at least in three independent 
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biological replicates and results are presented as mean ± standard deviation (s.d.) of 
the three biological replicates. 
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HomocysteineCompounds, like beta-aminopropionitrile (bAPN) and homocysteine (hcys), are known to inhibit a stable
matrix formation. Osteoblast-synthesized collagen matrix regulates the differentiation of precursor cells into
mature osteoblasts. They express lysyl oxidase, an enzyme involved in the collagen cross-linking process.
Lately, plasma hcys levels have recently been strongly correlated with fracture in humans. We have
previously shown that bAPN not only disturbs collagen cross-links but also affects osteoblastic differentiation
in a cell culture system.
The aim of the present study was to investigate the effects of bAPN and hcys on collagen cross-links and gene
expression at the mRNA level by FTIR and quantitative RT-PCR, respectively. We found that bAPN and hcys
down-regulated cell multiplication. While bAPN also down-regulated the metabolic activity of MC3T3-E1
cells, hcys down-regulated it by lower concentrations but up-regulated it by higher; both substances up-
regulated alkaline phosphatase activity. The substances increased the ratio of pyr/divalent cross-links of
collagen, and down-regulated mRNA expression of lysyl hydroxylase (Plod2) and lysyl oxidase (Lox), genes
which play an important role in the formation of a stable matrix. Furthermore, we demonstrate that both
substances stimulated the expression of Runx2, an indispensable regulator of osteoblastic differentiation.
However, analysis of genome wide mRNA expression suggests that hcys and bAPN have differential effects
on genes involved in osteoblastic differentiation and phenotype regulation.
The results indicate that although both bAPN and hcys affect collagen cross-link post-translational
modiﬁcations in a similar manner as far as pyr and divalent cross-links are concerned, they have differential
effects on the monitored genes expression at the mRNA level, with hcys exerting a broader effect on the
genome wide mRNA expression.
© 2009 Elsevier Inc. All rights reserved.Introduction
We have previously reported that beta-aminopropionitrile
(bAPN), a known lathyrogen, not only disrupts collagen cross-linking
but also affects osteoblastic activity and gene expression [1].
Homocysteine (hcys), a natural eukaryotic metabolite related to
several chronic pathologies such as cardio-vascular diseases has also
been shown to interfere with lysyl oxidase (Lox) action [2], altering
collagen post-translational modiﬁcations and cross-links. However,
an ambivalent classiﬁcation of hcys as lathyrogen is found in
literature. We have recently reported that there is a correlation
between plasma hcys levels and collagen cross-link ratio in forming
trabecular surfaces in humans [3]. Furthermore, recent clinical and
epidemiological data [4–7] report a correlation between blood hcys
levels and fracture risk. Clinical reports to the contrary also exist, as.
ll rights reserved.well as ones casting doubt as to whether hcys affects collagen cross-
linking [8–10]. The situation does not become clearer when animal
models are considered [11–15].
In the present study, using the preosteoblastic MC3T3-E1 cell
line, the effects of hcys and bAPN on cell viability, cross-link
formation and mRNA expression were compared as a function of
concentration. Using quantitative reserve transcription polymerase
chain reaction (qRT-PCR) and gene chip analysis, we investigated on
the effects of both substances on the expression of genes involved in
extracellular matrix formation, on general mRNA expression and on
differentiation factors. Concerning cell viability and multiplication as
well as expression of genes involved in post-translational collagen
cross-linking, both interventions affected collagen in a similar
manner. However, gene expression of selected gene groups res-
ponsible for the osteoblastic phenotype and development was
mostly differentially regulated by the used interventions. Further-
more, a general gene array analysis revealed that hcys regulated at
all concentrations more genes than bAPN and that the effects of hcys
were generally stronger.
704 R. Thaler et al. / Bone 46 (2010) 703–709When considered together, the results of the present study
show, in addition to collagen cross-linking inhibition, the breadth
by which bAPN and hcys affect osteoblastic function.
Materials and methods
Cell culture and matrix production
MC3T3-E1 cells (kindly donated by Dr. Kumegawa, Meikai
University, Department of Oral Anatomy, Sakado, Japan), a clonal
preosteoblastic cell line derived from newborn mouse calvaria, were
cultured in humidiﬁed air under 5% CO2 at 37 °C. Alpha-minimum
essential medium (α-MEM; Biochrom, Berlin, Germany) supplemen-
ted with 5% fetal calf serum (Biochrom), 50 μg/mL ascorbic acid
(Sigma), and 10 μg/mL gentamycin (Sigma) was used as culture
medium. For propagation, cells were subcultured twice a week using
0.001% pronase E (Roche) and 0.02% EDTA in Ca2+- and Mg2+-free
phosphate-buffered saline (PBS) before achieving conﬂuence.
MC3T3-E1 cells were seeded in culture dishes at a density of
20,000/cm2 and cultured overnight. On the next day, the medium
was changed and the cells were treated with or without bAPN
(Sigma) or hcys (Sigma) for 1 week to gain two to three cell layers
[16]. The various concentrations for the substances, the range of
whose was chosen based on previous publications, were 0.1 mM,
0.4 mM, 1 mM, and 4 mM. Given the breadth of the outcomes of the
gene array analysis, we decided for these speciﬁc experiments to
investigate an extra concentration for hcys (10 mM), given its
potential clinical signiﬁcance in relation to fracture. In vitro formed
extra-cellular matrix was subjected to Fourier-transform infrared
(FTIR) analysis for determination of collagen cross-link ratio.
The 7 day time point was chosen based on previously published
results that show that, in a cell culture system, collagen mRNA
expression and synthesis are at their respective highest at day 7,
whereas protein accumulation is at its lowest. When accumulation is
at its highest (at day 30), bothmRNA expression and protein synthesis
are at their respective minima [17]. Moreover, this makes the results
of the present study directly comparable with our previous report
concerning bAPN [1].
Cell multiplication, alkaline phosphatase activity (ALP), and viability
MC3T3-E1 cells were seeded in culture dishes at a density of
20,000/cm2 and cultured overnight. On the next day, themediumwas
changed and the cells were treated with or without the chemicals at
the various concentrations for 1 week. Cell number and ALP-activity
were analyzed. For determination of cell number (DNA amount
employed as surrogate), cell layers were washed with PBS and frozen
with 1 mM Tris–HCl buffer (pH 8.0) containing 0.1 mM EDTA. During
thawing, Hoechst 33258 dye (Polysciences, Warrington, PA) was
added (1 μg/mL) and, after an incubation of 15 min at room tem-
perature, the ﬂuorescence was measured (excitation 360, emission
465 nm). The amount of DNA was estimated using a standard curve
prepared from calf thymus DNA (Roche). Thereafter, alkaline phos-
phatase (ALP) activity was measured with p-nitrophenylphosphate
(2.5 mg/mL in 0.1 M diethanolamine buffer [pH 10.5], 150 mM NaCl,
2 mM MgCl2) by incubation of the cell layers for 15 min at room
temperature. Absorptionwasmeasured in amicroplate reader at 405/
490 nm. ALP activity (units per milligram DNA) was estimated using a
standard curve prepared fromcalf intestinal ALP (Roche). To assess cell
metabolic activity, a commercially available assay (EZ4U; Biomedica,
Vienna, Austria) was used, according to the protocol of the supplier.
FTIR imaging
After 7 days in culture, one well per experiment was processed
for spectroscopic analysis by FTIR Imaging for the determination ofpyr/divalent collagen cross-link ratio. The cells (7 day old cultures)
and ECM were ﬁxed in alcohol, scraped off the culture dishes, and
transferred onto barium ﬂuoride windows, where they were air-
dried. Following this, spectra were obtained in transmission with a
Bruker (Germany) Equinox 55 spectrometer coupled to a Bruker
Hyperion 3000 FTIR microscope equipped with a motorized stage
(±1 μm) and a 15× objective. The spectra were baseline-corrected
in the amide I and II spectral area (∼1500–1700 cm−1); water
vapor was subtracted and then subjected to second derivative
spectroscopy and curve ﬁtting routines as described elsewhere [18].
The collagen cross-link ratio was determined as previously
described [18].
Expression analysis by qRT-PCR
RNA was extracted using a RNA Isolation Kit (Qiagen), and cDNA
was synthesized from the mRNA using the 1st Strand cDNA
Synthesis Kit (Roche). The obtained cDNA was subjected to PCR
ampliﬁcation with a real-time cycler using TaqMan Gene Expression
Master Mix (Applied Biosystems) and TaqMan probes (Applied
Biosystems) for all genes monitored. 18S RNA was used as a
housekeeping gene for normalization, ampliﬁed in the same tube.
All PCRs were performed in triplicate. After 10 min of initial
denaturation at 95 °C, PCR was performed with 60 cycles: 10 s
denaturation at 95 °C, 30 s annealing, and extension at 60 °C.
Expression was quantiﬁed using the comparative quantiﬁcation
method [19].
Affymetrix GeneChip analysis
Total RNA was isolated using a RNA Isolation Kit (Qiagen).
Quality control of the RNA's as well as labeling, hybridization, and
scanning of the hybridized arrays was performed by the Kompe-
tenzzentrum fuer Fluoreszente Bioanalytik (KFB) (Regensburg,
Germany) using the mouse 430 2.0 chip (Affymetrix).
Statistical analysis
Each experiment was performed four times. Analysis by qRT-PCR
was performed as triplicate for each sample. Each measurement was
used for statistical analysis by ANOVA (Prism 4.0, GraphPad Software,
San Diego, CA). The data are represented as means±standard
deviation (SD).
Results
The effect of hcys and bAPN on cell multiplication and ALP activity
Cell metabolic activity, as well as cell number results are summa-
rized in Fig. 1. bAPN induced a dose-dependent reduction in both
outcomes (Figs. 1a, b). On the other hand, although hcys exhibited a
similar effect as far as cell number (DNA amount employed as a
surrogate) is concerned (Fig. 1d), a decrease in cell metabolic activity
was evident only for the lowest concentration employed, while the
higher ones had either no or even an increasing effect (Fig. 1c). Both
bAPN and hcys had a dose-dependent increasing effect on the ALP
activity of MC3T3-E1 cells (Fig. 2).
Hcys and bAPN inhibited cross-linking of collagen
Fig. 3 summarizes the effects of bAPN and hcys on the collagen
cross-link ratio (pyr/divalent). Both had an increasing effect on
this ratio (due to a disproportionate decrease in both cross-links)
as a function of concentration, with the exception of the lowest
concentration at which bAPN was similar to the untreated control
cultures.
Fig. 1. Results for cell viability expressed as optical density (OD) (a, c) and cell multiplication expressed as μgDNA/well (b, d) for hcys (white bars) and bAPN (black bars). bAPN
induced a dose-dependent reduction in both cell viability and cell multiplication (a, b), while hcys exhibited a similar effect as far as cell multiplication is concerned (d), and a
decrease in cell viability at the lowest concentration employed (c). The bars represent mean±SD. ⁎⁎Pb0.01; n=8; ⁎⁎⁎Pb0.001; n=8.
Fig. 2. Alkaline phosphatase activity results. After measuring the DNA content as a
surrogate of the cell number (Fig. 1), ALP activity was measured in the same well and
normalized to the amount of DNA. Both hcys (a) and bAPN (b) exhibited a dose-
dependent increasing effect in MC3T3-E1 cells. The bars represent mean±SD.
⁎⁎Pb0.01; n=8; ⁎Pb0.05; n=8.
705R. Thaler et al. / Bone 46 (2010) 703–709Hcys and bAPN regulated the expression of genes involved in collagen
cross-linking
First investigation focused on whether inhibition of cross-linking
by both substances also inﬂuenced the mRNA expression of the
genes involved in this process. Fig. 4 shows a signiﬁcant down-
regulation of Plod2 by both compounds at the higher concentrations.
Similar observations were made when expression of Lox, another
important enzyme for collagen post-translation modiﬁcations, was
monitored at the mRNA level: both bAPN and hcys had down-
regulating effects on the Lox expression when they were present at
higher concentrations in the culture media (Figs. 5a, b). The results
of the qRT-PCR were conﬁrmed by the results of the gene array,
where a down-regulation of Lox and Plod2 is shown as well (Table
1). Moreover, gene chip data demonstrated that Plod1 and the
Proline 4-hydroxylase alpha polypeptide I and II (P4ha1 and P4ha2)Fig. 3. Summary of the effects of bAPN and hcys on the collagen cross-link ratio (pyr/
divalent). Both had an increasing effect on this ratio as a function of concentration, with
the exception of the lowest concentration at which bAPN was similar to the control
cultures (no lathyrogen in the culture media). Provided P values indicate signiﬁcantly
different values vs. control cultures. The bars represent mean±SD. ⁎⁎⁎Pb0.01.
Fig. 4. Plod2 mRNA expression in hcys (a) and bAPN (b) treated MC3T3-E1 cells.
MC3T3-E1 cells were treated for 1 week with the listed concentration of lathyrogens.
Thereafter, mRNA was isolated, reverse transcribed, and subjected to qRT-PCR. The
speciﬁc gene expression was normalized to 18S RNA expression. At higher concentra-
tions, both substances decreased Plod2 mRNA levels signiﬁcantly. The bars represent
mean±SD. ⁎Pb0.05; n=12; ⁎⁎Pb0.01; n=12.
Fig. 5. Lox mRNA expression in hcys (a) and bAPN (b) treated MC3T3-E1 cells. MC3T3-
E1 cells were treated for 1 week with the listed concentration of lathyrogens.
Thereafter, mRNA was isolated, reverse transcribed, and subjected to qRT-PCR. At
higher concentrations, both substances decreased Lox mRNA levels signiﬁcantly. The
speciﬁc gene expression was normalized to 18S RNA expression. The bars represent
mean±SD. ⁎Pb0.05; n=12.
Table 1
Gene array analysis of genes involved in the post-translational cross-linking of collagen.
Fold increase in mRNA expression of the genes compared to untreated control culture
cells. Genes down-regulated beyond 1.3-fold are marked green.
706 R. Thaler et al. / Bone 46 (2010) 703–709were down-regulated (Table 1) showing a more pronounced effect
in the case of hcys treatment. Summarizing, the two compounds
inﬂuence in a similar manner the enzymatic activity as well as the
mRNA expression of genes involved in collagen post-translational
modiﬁcations. Furthermore, mRNA expression data obtained from
qRT-PCR were comparable to gene array data.
Impact of hcys and bAPN on the expression of genes of the osteoblastic
phenotype and bone development
Having demonstrated that both compounds disrupted collagen
cross-linking anddown-regulated the expression of genes important for
this process, the effect of the two compounds on the mRNA expression
of genes characteristic for the osteoblastic phenotype was studied.
Following recently published osteoblast differentiation schemas, at the
beginning of the differentiation (at the mesenchymal stem cell level),
three transcription factors Msx2, Dlx3, and Dlx5 are expressed in
temporal sequence [20,21]. Of these factors, only Dlx5 had a signal
strong enough to suggest mRNA expression and showed a trend to be
down-regulated by hcys (Table 2). Components of the transcription
complex AP-1 that are cFos, cJun, Fosl1, and FosB, are linked to skeletal
distortions. In our experiments, cJun was not regulated while cFos and
Fosl1 were down-regulated by hcys (Table 2).
During osteoblastic differentiation, the expression of the trans-
cription factors Runx2 and Osterix (Sp7) is known to be essential
[20,21]. Both factors were expressed in MC3T3-E1 cells, and as shown
in Table 2, Runx2 and Sp7 were up-regulated at least by about 140%
by both compounds, respectively. The gene array expression analysis
for Runx2 was conﬁrmed by qRT-PCR as shown in Fig. 6. Again the
extent of the regulation was consistent between both techniques.
Impact of hcys and bAPN on genes modulating Runx2 activity
The function of Runx2 is not only regulated by transcription but
interacting proteins modulate its activity as well. Co-activators of theable 2
ene array analysis of transcription factors involved in osteoblastic differentiation.
old increase of mRNA expression of the genes compared to untreated control culture
lls. Genes up- or down-regulated beyond 1.3-fold are marked in red or green,
spectively.T
G
F
ce
re
Table 3
Gene array analysis of genes modulating Runx2 activity.
Fold increase of the mRNA expression of the genes compared to untreated control
culture cells. Genes up-regulated over 1.3-fold are marked in red.
707R. Thaler et al. / Bone 46 (2010) 703–709Runx2 activity whose expression was suggested by gene array ana-
lysis are Aes, Myst3 and 4, as well asWwtr1 [22]. These genes were all
up-regulated by hcys but not affected by bAPN. A recently described
activator of Runx2 and with it of the osteoblastic differentiation is
Satb2 [22]. It works as a modular node in the transcriptional network
of osteoblastic differentiation [23] and was clearly up-regulated by
hcys. Also the co-repressors Tle2 and Stat1 were expressed, however,
only regulated by hcys as shown in Table 3.
Discussion
Recent clinical reports have debated whether plasma homocys-
teine levels are associated with fracture risk in humans [4–9,24–45].
Hcys has been reported to interfere with collagen post-translational
modiﬁcations [2] by inhibition of lysyl oxidase, an important enzyme
for collagen cross-link formation. We have reported that plasma hcys
levels are correlated with altered collagen cross-link ratio (pyr/
divalent) in humans [3], in a manner consistent with the action of a
lathyrogen. We have also reported that another “lathyrogen,” bAPN,
changes not only collagen cross-links but also osteoblastic prolifer-
ation and differentiation in a cell culture system [1]. The purpose of
the present study was to expand on our previous studies and compare
the effect of bAPN and hcys on collagen cross-links and on the gene
expression at the mRNA level of genes involved in post-translational
modiﬁcation of collagen cross-linking by qRT-PCR as a function of the
concentration of the substances. Moreover, gene array analysis was
performed to explore differences and potential mechanisms by which
these substances may regulate osteoblastic gene expression.
The results indicated that cell metabolic activity measured by the
EZ4U assay was decreased in the case of bAPN in a dose-dependent
fashion, while hcys decreased it at the lowest concentration (which is
within normal range in humans) and increased it at the higher one.Fig. 6. Runx2 mRNA expression in hcys (a) and bAPN (b) treated MC3T3-E1 cells.
MC3T3-E1 cells were treated for 1 week with the listed concentration of lathyrogens.
Thereafter, mRNA was isolated, reverse transcribed, and subjected to qRT-PCR. At
higher concentrations, both substances increased Runx2 mRNA levels signiﬁcantly. The
speciﬁc gene expression was normalized to 18S RNA expression. The bars represent
mean±SD. ⁎⁎Pb0.01; n=12.Interestingly, when the amount of DNA was measured as a surrogate
for cell number, both bAPN and hcys decreased the number in
accordance with the concentration. The hcys effect may be attributed
to the fact that it is known to arrest the cell cycle at the G1/S transition
via cyclin A2 transcriptional inhibition, dependent on cell type and
concentration [46]. Furthermore, both bAPN and hcys showed a
similar effect on the ALP activity; this result is in agreement with
previously published results [1,13].
FTIR spectroscopic analysis indicated that both bAPN and hcys
resulted in a dose-dependent increase of the pyr/divalent cross-link
ratio, due to a disproportionate reduction in both pyr and divalent
cross-links (data not shown), consistent with observations in our
study in humans investigating the relationship between plasma hcys
levels and collagen cross-link ratio [3].
Moreover, both compounds had not only a similar effect on the
collagen cross-link ratio monitored, but also down-regulated the
expression of Plod2 mRNA, an important enzyme for collagen post-
translation modiﬁcations, and one whose action precedes that of Lox
in collagen post-translational modiﬁcation cascade that was down-
regulated as well. The results of the qRT-PCR analyses were in
excellent agreement with the gene array data, conﬁrming the down-
regulation of Plod2 and Lox by both interventions.
Analysis of the data regarding the cross-linking process demon-
strated that bAPN and hcys had comparable effects. This is reﬂected by
the fact that both inhibited cross-linking and affected mRNA
expression of genes involved in post-translational modiﬁcations in a
similar manner: they down-regulated these genes.
These results suggest that both interventions act on two levels. The
disruption of cross-linking on the enzymatic level seems to be
ampliﬁed by the common down-regulation of the mRNA of the genes
involved in this process. The change in the ratio of the cross-links,
however, could be explained by differential inhibitory effects of the
interventions on responsible enzymes and/or inﬂuence on regulation
of expression of the genes coding for these enzymes. A common
regulation of these genes was found recently, where vitamin D [47] as
well as thyroid hormones (Varga et al., unpublished results) up-
regulated genes involved in collagen cross-linking, thus inﬂuencing
collagen quality. Common regulation of genes in osteoblasts could be
achieved by an upstream expressed transcription factor like the
osteoblast-speciﬁc Runx2 and Osterix. According to the schema of
Lian and Stein, during differentiation, osteoblasts express time depen-
dently a series of transcription factors and structure genes [21]. Both
compounds up-regulated the mRNA levels of Runx2 and Osterix,
which could regulate inversely the mRNA expression of Lox and
Plod2. Another possible explanation could be the common regulation
of those by Fosl1, which was down-regulated by both compounds.
Up-regulation of Runx2 and Osterix mRNA expression suggests that
bAPN and hcys accelerate osteoblastic differentiation inMC3T3-E1 cells,
which is further conﬁrmedby the increaseof theALPactivity. This is also
supported by the down-regulation of Dlx5 mRNA expression, a gene
that precedes Runx2 during osteoblastic differentiation. However,
708 R. Thaler et al. / Bone 46 (2010) 703–709Runx2 is not only regulated at itsmRNAexpression level, but interacting
proteins modulate its enzymatic activity as well. Interestingly, the
mRNA expression of many of these Runx2 interacting proteins is up-
regulated by hcys but not by bAPN. These results suggest that, although
bAPN and hcys affect Runx2 mRNA expression in a similar manner, at
this stage, the activity of Runx2 and with it the osteoblastic
differentiationdepends on the expression of Runx2 interactingproteins,
which may be affected by both compounds differentially.
A general evaluation of genomewide gene expression revealed that
only a small part of genes is co-regulated by both compounds. 5.5-fold
more genes are down- and 3.8-fold more genes are up-regulated by
hcys compared to bAPN (not shown). This ﬁnding could be due to the
fact that hcys being a physiological metabolite is involved and affects
many intracellular metabolic pathways. The common regulated genes,
however, could be exposed to the “lathyritic” effect of the agents.
For this study, we used 0.1 and 4 mM for bAPN and hcys, and for
the latter we used an additional concentration of 10 mM. The lower
concentration used resembles the “pathological” one, while the higher
one was used to accentuate signiﬁcant effects on gene expression.
As previously stated, hcys stimulated expression of genes involved
in the regulation of Runx2 function, while bAPN did not. Runx2
function, essential for the development of the osteoblastic phenotype,
can be activated or inactivated at the protein level. Our results
demonstrate that hcys has the capacity to up-regulate both co-
activators and in-activators. This may imply that through their
receptors, the local environment (growth- and differentiation factors,
ECM) of the cells, and the hormonal status of an individual inﬂuence
the expression and activity of co-activators and in-activators. This
suggests that the physiological and hormonal status of an individual
regulates the expression of these in/co-activators, which have diffe-
rent impact on Runx2 function and consequently on the osteoblast
activity. As an example, one may consider Stat1, a co-repressor, and
Satb2, an activator of Runx2, both of which were up-regulated by
hcys; the local environment or the hormonal status, however, will
dictate whether Runx2 is either activated or repressed. This suggests
that each individual may be differentially inﬂuenced by hcys. This
could explain some contradictory results found in the literature with
hcys concerning bone quality [4–6,8–10,48].
In summary, the results of the present study demonstrated that
concerning collagen cross-linking both compounds not only act as
lathyrogens inﬂuencing the enzymatic activity of genes involved in
collagen cross-linking but they also inﬂuence on a similar manner the
mRNA expression of these genes. Furthermore, induction of differen-
tiation is suggested for both compounds by their up-regulating effect
on Runx2 mRNA expression. However, in the case of hcys which
simultaneously up-regulates co-activators and repressors of the
Runx2 activity, the net effect on differentiation may depend on the
local environment (individual). Finally, gene array analysis revealed
that hcys regulated considerably more genes in MC3T3-E1 cells
compared to bAPN. All these data emphasize that bAPN and hcys not
only have comparable, but also have differing effects on osteoblasts.
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Homocysteine Suppresses the Expression of the Collagen
Cross-linker Lysyl Oxidase Involving IL-6, Fli1, and Epigenetic
DNAMethylation*
Received for publication, July 20, 2010, and in revised form, November 14, 2010 Published, JBC Papers in Press,December 9, 2010, DOI 10.1074/jbc.M110.166181
Roman Thaler‡, Marlies Agsten‡, Silvia Spitzer‡, Eleftherios P. Paschalis‡, Heidrun Karlic§, Klaus Klaushofer‡,
and Franz Varga‡1
From the ‡Ludwig Boltzmann Institute of Osteology, Hanusch Hospital, Wiener Gebietskrankenkasse and AUVA Trauma Center
Meidling, 1st Medical Department, Hanusch Hospital, 1140 Vienna, Austria and the §Ludwig Boltzmann Institute for Leukemia
Research and Hematology, Hanusch Hospital and Ludwig Boltzmann Cluster Oncology, 1140 Vienna, Austria
Elevated homocysteine (Hcys) serum levels represent a
risk factor for several chronic pathologies, including cardio-
vascular disease, atherosclerosis, and chronic renal failure,
and affect bone development, quality, and homeostasis.
Hcys influences the formation of a stable bone matrix di-
rectly through the inhibition of the collagen cross-linking
enzyme lysyl oxidase (Lox) and, as we have shown recently,
by repressing its mRNA expression. The aim of this study
was to investigate the mechanisms involved in this process.
Through evaluation of gene arrays, quantitative RT-PCR,
immunoblots, and ELISA, we identified a Hcys-dependent
stimulation of interleukin 6 (IL-6) and genes involved in
IL-6/Janus kinase 2 (JAK2)-dependent signal transduction
pathways in pre-osteoblastic MC3T3-E1 cells. Moreover,
up-regulation of genes essential for epigenetic DNA methyl-
ation (DNA (cytosine-5)-methyltransferases and helicase
lymphoid-specific (Hells) was observed. Further investiga-
tions demonstrated that Hcys increased via IL-6/JAK2 the
expression of Fli1 (Friend leukemia virus integration 1), a
transcription factor, which we found essential for IL-6-de-
pendent Dnmt1 stimulation. CpG methylation analysis of
CpG-rich Lox proximal promoter revealed an increased
CpG methylation status after treatment of the cells with
Hcys indicating an epigenetic origin for Hcys-dependent
Lox repression. Inhibition of the IL-6/JAK2 pathway or of
CpG methylation reversed the repressive effect of Hcys on
Lox expression. In conclusion, we demonstrate that Hcys
stimulates IL-6 synthesis in osteoblasts, which is known to
affect bone metabolism via osteoclasts. Furthermore, IL-6
stimulation results via JAK2, Fli1, and Dnmt1 in down-reg-
ulation of Lox expression by epigenetic CpG methylation
revealing a new mechanism negatively affecting bone matrix
formation.
Epidemiological studies have shown that high homocys-
teine (Hcys)2 serum levels represent a risk factor for several
chronic disorders such as cardiovascular disease, atheroscle-
rosis, chronic renal failure, diabetes, or the metabolic syn-
drome (1, 2). Moreover, hyperhomocysteinemia is known to
affect bone development and homeostasis (3–6). Hcys has
been shown to interfere with post-translational modifications
of collagen directly by inhibiting lysyl oxidase (Lox) (7) and
indirectly by down-regulation of its mRNA expression and of
other genes involved in collagen cross-linking. Enzymatic in-
hibition or mRNA down-regulation of Lox results in changes
in collagen cross-linking pattern in vitro (8–10) and in vivo
resulting in decreased bone quality (11–13). In this context,
we have recently reported a correlation between plasma Hcys
levels and a collagen cross-link ratio in forming trabecular
surfaces in human bone (14).
Lysyl oxidase was also identified as a phenotypic suppressor
of the ras oncogene in H-ras-transformed NIH3T3 fibro-
blasts. In this transformed cell line, H-ras participates in an
elaborate pathway attenuating the expression of Lox and of
many other genes by CpG methylation on DNA. These genes
are reactivated by treatment with azacytidine, an inhibitor of
DNA (cytosine-5)-methyltransferases. Methylation of cyto-
sine-guanine dinucleotides (CpGs) on DNA is an important
epigenetic mechanism involved in the selective regulation of
gene expression and in the stabilization of chromatin, thus
controlling tissue development and pathogenesis. Aberrant
CpG methylation of specific genes is often found in many tu-
mors and tumorigenic cell lines (15).
Besides its role as inhibitor of collagen cross-linking, Hcys
is also known to play a role in epigenetic gene regulation be-
ing directly involved in the DNA methylation process. Hcys
represents a methyl group carrier involved in the S-adenosyl-
methionine-S-adenosylhomocysteine methylation cycle. Here,
Hcys is remethylated to methionine, which is further acti-
vated to S-adenosylmethionine, the methyl donor in DNA
methylation. S-Adenosylmethionine converts to S-adenosyl-
homocysteine after DNA methylation. Hydrolysis of S-adeno-
sylhomocysteine to homocysteine completes the cycle (16).
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Nevertheless, in contrast to other cells and tissues, to date
sparse research has been performed regarding the significance
of epigenetic gene regulation for bone development and
pathogenesis. We have recently demonstrated that mainte-
nance of global and specific DNA methylation by collagen
type I, the main component of extracellular matrix in the
bone, plays an important role in osteoblastic survival (17).
Furthermore, we have shown that Hcys affects osteoblastic
development and differentiation by altering the expression of
osteoblastic genes already at the mRNA level (9).
Assuming an epigenetic cause, in this study we demon-
strate the mechanisms involved in suppression of Hcys of Lox
mRNA expression in pre-osteoblastic MC3T3-E1 cells. Be-
sides the known role of Hcys as a metabolite in the DNA
methylation cycle (16), we investigated if Hcys has an impact
on the expression of genes involved in DNA methylation such
as DNA methyltransferases and helicase, lymphoid-specific
(Hells). Thereby we found that Hcys regulates the expression
of DNA methyltransferase 1 (Dnmt1) by inducing a signaling
pathway where interleukin 6 (IL-6), Janus kinase 2 (Jak2), and
Friend leukemia virus integration 1 (Fli1) transcription factors
were involved. These findings suggest a key role of epigenetic
DNA methylation in Hcys-mediated Lox suppression.
MATERIALS ANDMETHODS
Cell Culture—MC3T3-E1 cells (kindly donated by Dr. Ku-
megawa, Department of Oral Anatomy, Meikai University,
Sakado, Japan), a clonal pre-osteoblastic cell line derived from
newborn mouse calvariae, were cultured in humidified air
under 5% CO2 at 37 °C. -Minimum essential medium (Bio-
chrom, Berlin, Germany) was supplemented with 5% fetal calf
serum (Biochrom, Germany), 50 g/ml ascorbic acid (Sigma),
and 10 g/ml gentamycin (Sigma). For propagation, cells
were subcultured twice a week using 0.001% Pronase E
(Roche Applied Science) and 0.02% EDTA in Ca2- and
Mg2-free phosphate-buffered saline (PBS) before achieving
confluence. For experiments, MC3T3-E1 cells were seeded in
culture dishes at a density of 20,000/cm2 and cultured over-
night. The next day, the medium was changed, and the cells
were treated with Hcys (Sigma) at the indicated concentra-
tions for 3, 6, or 14 days.
To demonstrate the effect of Hcys on the JAK2 pathway or
on DNA methylation, cells were treated with 3.6 mM Hcys for
3 days; thereafter, 30 M of the specific JAK2 inhibitor AG490
(Calbiochem) or 50 M of the DNA methylation inhibitor
zebularine (Sigma) was added to the medium for a further 3
days. To test the effects of recombinant mouse IL-6 protein
(PeproTech, United Kingdom) on the cells, they where cul-
tured with increasing concentrations (3–30 ng/ml) for 36
and 48 h. To demonstrate the IL-6-dependent activation of
the JAK2 pathway by Hcys, cells were treated with 3.6 mM
Hcys for 3 days; thereafter, 4 g/ml IL-6 antibody (Ab)
(PeproTech) was added to the medium for a further 3 days.
Isolation of Nucleic Acids and mRNA Expression Analysis by
qRT-PCR—DNA and RNA were extracted using a DNA/RNA
isolation kit (Qiagen). cDNA was synthesized from about 0.5
g of RNA using the First Strand cDNA synthesis kit as de-
scribed by the supplier (Roche Applied Science). The ob-
tained cDNA was subjected to PCR amplification with a real
time cycler using FastStart SYBR Green master mix (Roche
Applied Science) for the genes Dnmt1, Dnmt3b, Hells, and
Fli1 (for primer design see Table 1). SYBR Green PCR was
started with 10 min of an initial denaturation step at 95 °C
and then continued with 45 cycles consisting of 30 s of dena-
turation at 95 °C, 30 s annealing at primer-specific tempera-
tures, and extension at 72 °C. For Lox expression, we used a
TaqMan probe (Mm00495386_m1, Applied Biosystems), and
for normalization we used the 18 S RNA TaqMan probe
(4319413E, Applied Biosystems), both in combination with
TaqMan gene expression master mix (Applied Biosystems)
with an initial denaturation at 95 °C for 10 min followed by 45
cycles alternating between 60 and 90 °C. All PCRs were per-
formed in triplicate, and expression was evaluated using the
comparative quantitation method (18). For each experiment,
the triplicate results of the qRT-PCR were averaged, and this
mean value was treated as a single statistical unit. The data of
the experimental results are presented as means S.D.
Affymetrix GeneChip Analysis—Total RNA was isolated
using an RNA isolation kit (Qiagen). Quality control of the
RNAs as well as labeling, hybridization, and scanning of the
hybridized arrays was performed by the Kompetenzzentrum
fuer Fluoreszente Bioanalytik (KFB) (Regensburg, Germany)
using the mouse 430 2.0 chip (Affymetrix).
IL-6 Quantification by ELISA—For IL-6 ELISA, MC3T3-E1
cells were seeded in triplicate and treated with or without the
indicated Hcys concentrations for 14 days as described above.
After 3, 6, and 14 days of Hcys treatment, 1 ml of culture su-
pernatant was saved and stored at80 °C. For IL-6 quantifi-
cation, 96-well ELISA plates (Iwaki) were prepared by using
the murine IL-6 ELISA development kit as described by the
supplier (PeproTech). IL-6 concentration was monitored by
color development of 2,2-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid) liquid substrate (Sigma) with an ELISA plate
reader (Glomax, Promega) at 405 nm with wavelength correc-
tion set at 650 nm. Every cultured well was measured in tripli-
cate; these triplicate results were averaged, and the mean
value was treated as a single statistical unit. The complete
experiment was performed twice.
Protein Isolation and Immunoblotting—For protein extrac-
tion, cell layers were washed two times with PBS and scraped
in SDS sample buffer (2% SDS, 100 mM -mercaptoethanol,
125 mM Tris-HCl, pH 6.8) and heated at 95 °C for 5 min. 30
g of protein extracts were fractionated on 8 or 10% SDS-
PAGE for Dnmt1 or the other proteins, respectively. Follow-
ing SDS-gel electrophoresis, the proteins were transferred to
nitrocellulose filters (Millipore) and blocked overnight with
10% blocking reagent (Roche Applied Science) in TN Buffer
(50 mM Tris, 125 mM NaCl, pH 8). Subsequently, the filters
were incubated for 1 h at room temperature with antibodies
against FLI1 ((C19), HELLS (Lsh, H-240)), LOX (H-140),
DNMT1 (K-18, all Santa Cruz Biotechnology) diluted 1:200 in
blocking buffer. Afterward, all filters were washed three times
with immunoblot wash buffer (TN buffer containing 0.01%
Tween) and the FLI1, HELLS, and LOX blots were incubated
for an additional hour with an anti-mouse IgG/anti-rabbit IgG
horseradish peroxidase (HRP)-labeled secondary antibody
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(Roche Applied Science) diluted 1:20,000 in blocking buffer.
The Dnmt1 blot was incubated for 1 h with an anti-goat IgG
HRP-labeled secondary antibody (Sigma) diluted 1:160,000 in
blocking buffer. Finally, the blots were washed again three
times with immunoblot washing buffer before detection of
light emission with the BM chemiluminescence Western blot-
ting kit (Roche Applied Science) as described by the supplier.
Chemiluminescence was measured with an image acquisition
system (Vilber Lourmat, France).
Cloning of Mouse Dnmt1 Promoter—To study the effect of
IL-6 on Dnmt1 promoter activity, four fragments of the
mouse Dnmt1 promoter (NC_000075.5) were cloned from
MC3T3-E1 genomic DNA into the pGEM T-easy vector (Pro-
mega) by using the following 5-primers elongated to contain
a BglII restriction site (underlined): TCG AGA TCT GCC
TTC GGG CAT AGC ATG GTC for a 220-bp fragment car-
rying three putative Fli1-binding sites (as suggested in Ref.
19), at30,60, and96 bp from the somatic transcrip-
tional start site (20); TCG AGA TCT GCC TGT GTG GTA
CAT GCT GC for the 190-bp fragment carrying two putative
Fli1-binding sites (at30 and60 bp); TCG AGA TCT GGC
CGC CCC CTC CCA ATT GG for the 160-bp fragment car-
rying one putative Fli1-binding site (at30 bp); and TCG
AGA TCT GCG AAA AAG CCG GGG TCT CGT TC for the
150-bp fragment carrying no FLI1-binding sites. As 3-primer
we used GCC TGC GGA CAT GGT CCG GGA GCG AGC
CTG. These fragments were subsequently cloned into the
secreted alkaline phosphatase 2 (SEAP2) reporter vector
(Clontech) by using BglII and EcoRI restriction enzymes
(Fig. 1a).
To generate mutated Dnmt1-SEAP2 fragments, as de-
scribed previously (19), the following primers with modified
putative FLI1-binding sites were designed (mutation sites
form 5- TTCC to TTAA are underlined): 5 CGG GCA TAG
CAT GGT CTT AAC CCA CTC TCT TGC CCT G and com-
plementary 3 CAG GGC AAG AGA GTG GGT TAA GAC
CAT GCT ATG CCC G for the putative FLI1-binding site at
96 bp from the somatic transcriptional start site; 5 GTG
GTA CAT GCT GCT TAA GCT TGC GCC GCC CC and
complementary 3 GGG GCG GCG CAA GCT TAA GCA
GCA TGT ACC AC for the putative FLI1-binding site at60
bp from the somatic transcriptional start site; and 5 CTC
CAA ATT GGT TTA AGC GCG CGC GAA AAA GCC G
and 3 CGG CTT TTT CGC GCG CGC TTA AAC CAA
TTG GGA G for the putative FLI1-binding site at30 bp
from the somatic transcriptional start site.
For transfection experiments with the various SEAP2-
Dnmt1 vectors, SEAP2-control vector and the SEAP2-basic
vector, MC3T3-E1 cells were seeded at 20,000 cells/cm2 in 48
multiwell plates. Six hours after seeding, cells were trans-
fected with 0.15 g/cm2 vector construct using 1 g/cm2
DOSPER transfection reagent (Roche Applied Science)
following the suppliers’ protocol. After 2 days, cells were
treated for a further 3 days with 30 ng/ml of murine IL-6
(PeproTech), and finally, SEAP2 activity was measured in 50
l of culture supernatant using the SEAP2 bioluminescence
kit (Roche Applied Science) following the supplier’s instruc-
tions. Each experiment was run in quadruplicate and was re-
peated at least twice.
Chromatin Immunoprecipitation of Fli1 Bound on Dnmt1
Promoter—As numerous members of the E-twenty six tran-
scription factor family can bind to GGAA (TTCC) sequence
in vitro, chromatin immunoprecipitation (ChIP) assay
were performed to demonstrate FLI1 TTCC occupancy at the
Dnmt1 locus in vivo. For this purpose, MC3T3-E1 cells were
treated for 6 days with or without 3.6 mM Hcys. Subsequent
chromatin cross-linking, cell lysis, chromatin sharing, FLI1
immunoprecipitation, and DNA clean-up were performed
with the ChampionChip one-day kit (SABiosciences, MD)
following the manufacturer’s instructions. Chromatin from
untreated as well as from Hcys-treated cells was incubated
overnight on a rotor at 4 °C with 4 g of anti-FLI1 antibody
(C-19, Santa Cruz Biotechnology) or with 4 g of nonimmune
serum as negative control. Before immunoprecipitation, 1%
(10 l) of the chromatin was saved and stored at 4 °C for fur-
ther use as reference. For quantitation of the qRT-PCR values,
for each sample, DNA signal of the FLI1-precipitated chroma-
tin was normalized to the unprecipitated chromatin (for
ChIP-Dnmt1 promoter primer design see Table 1).
Lox Promoter Methylation—To test if down-regulation of
Lox by Hcys is due to CpG methylation, CpG content on Lox
promoter was analyzed. A CpG-rich region starting from ap-
FIGURE 1. Schematic diagram depicting Dnmt1 (a) and Lox (b) promoter. a, exon representing the somatic transcription start (marked with 1) is repre-
sented as small open box (untranslated region) and large black arrow (translated region). The three putative FLI1-binding sites are shown as gray boxes.
Forward (fw) cloning primers annotated with the resulting amplicon size and reverse (rv) cloning primer are marked aswhite arrows. Binding sites of amplifi-
cation primers for Fli1 ChIP analysis are marked as black arrows. The numbers below the gene line denote the distance to the transcription start. b, represen-
tation of Lox proximal promoter and the first exon showing the fragment used for methylation analysis (gray line). Lox genomic structure shows a part of
the first exon (475 bp), including 374 bp of the 5-untranslated region (open box) and the first 101 bp of the coding region (black arrow). To generate a suita-
ble fragment (gray line) for methylation analysis by “Methyl Miner” assay, DNA was restricted by MboII restriction enzyme (M). Forward (fw) and reverse (rv)
primers for subsequent amplification by qRT-PCR are marked aswhite arrows. The vertical bars indicate the CpGs in the DNA strand, and the numbers below
the gene line denote the distance to the transcription start.
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proximately600 bp 5 from the transcriptional start site and
spanning over the first exon was selected. An appropriate
fragment of the targeted Lox region was generated by diges-
tion of 1 g of genomic DNA with 40 units of the CpG meth-
ylation-insensitive restriction enzyme MboII (New England
Biolabs) for 20 min at 37 °C from cells cultured for 6 and 14
days with or without 3.6 mM Hcys. Subsequently, the enzyme
was heat-inactivated at 65 °C for 20 min. As shown in Fig. 1b,
the generated fragment has 627 bp and contains 30 CpG sites.
It includes 243 bp of the proximal promoter region and 312
bp of the untranslated part of the first exon of Lox. After
MboII digestion, DNA was purified using a commercially
available PCR clean-up kit following supplier’s instructions. In
the next step, methylated DNA fragments were captured with
the “Methyl Miner methylated DNA enrichment kit” (Invitro-
gen) following the supplier’s instructions. In brief, methylated
DNA was captured by methyl-binding protein 2 (MBD2) cou-
pled to magnetic beads and subsequently separated from the
unmethylated DNA fraction. Methylated DNA was eluted
from the MBD2 beads with 200 l of a 2 M NaCl solution as a
single fraction and concentrated by ethanol precipitation. Fi-
nally, the mean methylation status of the fragments was de-
termined by amplifying the fragments by quantitative real
time PCR. Amplification ratios of the bound (methylated)
DNA fraction to unbound (unmethylated) DNA fraction were
calculated (for primer design see Table 1).
Statistical Analysis—Statistical analyses were performed
using either analysis of variance or Student’s t test using
Prism 4.03 (GraphPad Software, San Diego). p 0.05 was
considered as significant. Results are presented as mean
S.D.
RESULTS
Homocysteine Stimulates IL-6 Expression thus Affecting
JAK2-dependent Signaling Pathways in MC3T3-E1 Cells—As
we already have demonstrated by genome-wide expression
studies, Hcys affects the expression of genes of the osteoblas-
tic phenotype (9). Further analysis of the data suggested that
Hcys regulated the mRNA expression of IL-6 and of genes
involved in JAK2 signal transduction pathways (Table 2),
which are activated by this cytokine (21, 22).
To understand the temporal dynamics, time and dose de-
pendence of Hcys on MC3T3-E1 cells was studied. Because of
variation of basal expression of IL-6 mRNA expression as
measured by qRT-PCR, by ELISA, we measured IL-6 protein,
which accumulates in the culture medium. Generally, the pri-
mary data measured by ELISA showed a decreasing trend for
the basal IL-6 expression (from 0.56 ng/ml IL-6 expression
after 3 days to 0.33 ng/ml IL-6 expression after 14 days, data
not shown). As shown in Fig. 2, after 3 days of Hcys treat-
ment, no significant changes in IL-6 expression could be ob-
served in the pre-osteoblastic cell line. However, after 6 days
of Hcys treatment, IL-6 expression strongly increased in a
concentration-dependent manner showing a maximal up-
FIGURE 2.Hcys up-regulates IL-6 in MC3T3-E1 pre-osteoblasts. After 6
days (d) of treatment with 3.6 mM Hcys, expression of the JAK2 activator IL-6
was significantly enhanced in the MC3T3-E1 pre-osteoblastic cell line when
compared with untreated cultures (Co). After 14 days of treatment, the up-
regulative effect of Hcys on IL-6 expression was reduced but remained sig-
nificant at the highest concentration used. No effects were observed after 3
days of culture with Hcys. To analyze IL-6 expression, cell medium superna-
tant was saved, and IL-6 expression was measured by ELISA. Values are rep-
resented as mean S.D.; untreated control is set to 1, and treated probes
are referred as fold change to control. *, p 0.05; **, p 0.01; ***, p
0.001; n 6.
TABLE 1
qRT-PCR primer for mRNA expression and Lox CpGmethylation analysis (SYBR Green)
Gene Forward primer (5–3) Reverse primer (5–3) Tm
°C
Dnmt1 ACCGCTTCTACTTCCTCGAGGCCTA GTTGCAGTCCTCTGTGAACACTGTGG 62
Dnmt3b GGAGAAAGCCAGGGT AAGAGGGGGTGGAAGGA 63
Hells TGAGGATGAAAGCTCTTCCACT ACATTTCCGAACTGGGTCAAAA 63
Fli1 ATGGACGGGACTATTAAGGAGG GAAGCAGTCATATCTGCCTTGG 62
Primer for Lox CpGmethylation analysis
Promoter/first exon GCATGTTCGGCCCAGATTAAGTCG CAGAGTCTGGAGTAGAAGGAGGAGG 65
Primer for FLI1 ChIP analysis on Dnmt1 promoter
Dnmt1 ChIP-FLI1 CTTCCCCCACTCTCTTGC GAACAGCTCTGAACGAGAC 63
TABLE 2
Regulation of genes involved in the JAK/STAT signal transduction
pathway as suggested by genome-wide expression analysis
Fold regulation means change in expression level at a given concentration divided
by that of the untreated cultures.
Fold regulation to untreated control
Gene symbol 0.108 mM 3.6 mM 10.8 mM
Il6 1.06 1.51 2.37
Il6ra 1.01 1.06 1.09
Il6st 1.04 1.21 1.31
Jak1 1.22 1.12 1.08
Jak2 1.74 1.61 1.74
Jak3 1.30 1.16 1.29
Stat1 1.59 3.06 3.44
Stat2 2.52 3.97 3.31
Stat3 1.21 1.08 1.14
Stat4 1.11 1.28 1.10
Stat5a 1.24 1.10 1.03
Stat5b 1.09 1.03 1.07
Stat6 1.20 1.15 1.41
Cbl 1.41 1.96 2.02
Cblb 1.28 1.16 1.35
Cblc 1.11 1.39 1.56
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regulation of 4.4-fold (corresponding to 1.83 ng/ml IL-6) at
3.6 mM Hcys (p 0.001) in the culture medium when com-
pared with untreated cultures. After 14 days of treatment, the
Hcys effect on IL-6 expression was attenuated but was still
significant at 3.6 mM (p 0.01). In Table 3, we present the
regulation of those genes that will be described in more detail
later to demonstrate the epigenetic influence of Hcys on Lox
regulation.
Dnmt1 mRNA Expression Is Up-regulated by IL-6 via Puta-
tive FLI1-binding Sites on Dnmt1 Promoter in MC3T3-E1
Cells—Recently, it was demonstrated that IL-6 activates the
transcription of DNMT1 via FLI1 in human erythroleukemia
cells (19, 23). Fig. 3 demonstrates that a comparable pathway
exists in mouse osteoblasts as well. IL-6 significantly in-
creased Fli1 after 36 h and tended to stimulate expression
after 48 h (Fig. 3a), although Dnmt1mRNA expression did
not increase significantly until after 48 h of treatment (Fig.
3b). Dose dependence of the expression of both genes at the
time when expression was significantly increased demon-
strates that a maximum effect was found already at 3 ng/ml
IL-6 (Fig. 3, c and d); this value was in the same order of mag-
nitude as found in the culture medium after Hcys treatment
of MC3T3-E1 cells as mentioned above (1.83 ng/ml).
Fig. 1a depicts three putative FLI1-binding sites (sequence
GGAA) in the first 220 bp of the somatic Dnmt1 promoter
(20), which are similarly organized in the human counterpart
(19). To test if IL-6 mediated the increase of Dnmt1 transcrip-
tion via these binding sites, reporter-vector constructs of the
Dnmt1 gene with different lengths were constructed and
transfected into MC3T3-E1 cells. As depicted in Fig. 1a, four
different truncations were created as follows: a 150-bp frag-
ment without any putative FLI1-binding site and three other
fragments with 160, 190, and 220 bps containing one, two, or
three putative FLI1-binding sites at30,60, or96 bp,
respectively. After 72 h of IL-6 treatment, SEAP2 activity was
measured in the culture supernatant. As shown in Fig. 4a,
when compared with the respective untreated promoter vec-
tors, an IL-6-dependent increase of Dnmt1 promoter activity
correlated with an increasing promoter length and/or an in-
creasing number of GGAA sites in the promoter. The stron-
gest IL-6 effect was observed for the vector containing an in-
sert of 220 bp (3 GGAA sites) of Dnmt1 promoter with an
increase of 2.2-fold (p 0.05) when compared with the un-
treated vector.
To ensure that the IL-6-mediated effect on the activity of
the Dnmt1 promoter was due the predicted sites, in the
220-bp Dnmt1 promoter-reporter construct these sites were
mutated. After transfection into MC3T3-E1 cells and treat-
FIGURE 3. Fli1 (a) andDnmt1 (b) mRNA expression after treatment of MC3T3-E1 cells with 30 ng/ml recombinant murine IL-6 for 36 and 48 h. Com-
pared with untreated control (Co), Fli1mRNA expression is significantly up-regulated after 36 h of IL-6 treatment, whereas Dnmt1 mRNA expression remains
unaffected at this time. After 48 h, 12 h after Fli1 stimulation, Dnmt1 also shows a significant increase in mRNA expression by IL-6 treatment. At this time,
Fli1mRNA expression is still increased by IL-6; however, the regulation is not significant. As shown in c and d, treatment of the cells with increasing concen-
trations of IL-6 at the times showing significant mRNA stimulation for Fli1 and Dnmt1 revealed a significant up-regulation for both genes already at 3 ng/ml
IL-6 in culture medium. The up-regulative effect of the cytokine was already reached at this concentration saturation for both genes. To analyze mRNA ex-
pression of Fli1 and Dnmt1, RNA was isolated and analyzed by qRT-PCR. Gene expression was normalized to 18 S rRNA. Treated probes are referred as fold
change to untreated control; *, p 0.05; **, p 0.01; ***, p 0.001. For all graphs n 3.
TABLE 3
Regulation of genes involved in the DNAmethylation process as
suggested by genome-wide expression analysis
Regulation of these genes was verified by qRT-PCR and, except for Dnmt3b, by
ELISA or immunoblots. Fold regulation means change in expression level at a
given concentration divided by that of the untreated cultures.
Fold regulation to untreated control
Gene symbol 0.108 mM 3.6 mM 10.8 mM
Il6 1.06 1.51 2.37
Fli1 1.18 1.15 1.40
Dnmt1 1.09 1.51 1.76
Dnmt3b 1.34 1.09 1.25
Hells 1.04 2.45 3.60
Lox 1.07 1.67 1.64
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ment with IL-6 for 72 h, SEAP2 activity was measured in cul-
ture supernatant again. As shown in Fig. 4b, mutation of these
binding sites reduced transcription of the Dnmt1 promoter-
reporter construct, where mutation of site 3 (see Fig. 1)
showed the strongest effect.
Hcys Up-regulates the Transcription Factor Fli1 via IL-6
and JAK2 in MC3T3-E1 Cells—Hcys regulated Fli1 mRNA
expression similarly to IL-6. After 3 days of Hcys treat-
ment, no effect on mRNA expression of Fli1 was observed.
Subsequently, the highest Hcys-mediated increase of Fli1
mRNA expression was observed after 6 days of treatment
reaching a 2.1-fold (p 0.01) up-regulation when compared
with control. After 14 days of treatment, the Hcys effect on
Fli1 expression was attenuated but was still significant (p
0.01, Fig. 5a).
Addition of anti-IL-6 antibody (Fig. 5b) or of the JAK2 in-
hibitor AG490 (Fig. 6) for the last three culture days to 6 days
Hcys (3.6 mM)-treated MC3T3-E1 cells abrogated the Hcys
effect on Fli1mRNA and protein expression (Fig. 6, a–c).
This indicates that Hcys regulates Fli1 expression via IL-6/
JAK2. No effect of the Ab or of AG490 was found on basal
Fli1 expression.
Hcys Stimulates the Expression of Genes Involved in Epige-
netic DNAMethylation—Gene chip analysis indicated an
Hcys-dependent mRNA up-regulation of genes involved in
DNA methylation (Table 3). The results on the regulation of
DNA methylation-related genes obtained by gene chip analy-
sis were confirmed by qRT-PCR. Furthermore, Dnmt1 and
Hells expressions were also studied by immunoblot analysis.
As shown, when compared with untreated controls, after 3
days of culture 3.6 mM Hcys slightly induced the mRNA ex-
pression of Dnmt1 (Fig. 7a) and Dnmt3b (Fig. 9) and signifi-
cantly induced (p 0.05) the mRNA expression of Hells (Fig.
8a). However, after 6 days of treatment, Hcys up-regulated
the mRNA expression of all three genes significantly. At this
time, Hcys increased the mRNA expression of Dnmt1 1.80-
fold (p 0.01, Fig. 7a), the DNMT1 protein expression 3.13-
fold (p 0.05, Fig. 7, b and c), the mRNA expression of Hells
3.1-fold (p 0.05, Fig. 8a), the protein expression of HELLS
1.78-fold (p 0.05, Fig. 8, b and c), and the mRNA expression
of Dnmt3b 1.84-fold (p 0.001, Fig. 9) when compared with
untreated control. After 14 days of Hcys treatment, the
mRNA expression of all three genes was still significantly in-
creased (Figs. 7a, 8, and 9).
FIGURE 4. a, as measured by reporter gene assay, Fli1-binding sites/promoter length correlated with the IL-6-dependent activation of the Dnmt1 promoter.
A significant increase in promoter activity by IL-6 was seen when the putative FLI1-binding sites at60 bp (190-bp fragment) and at96 bp (220-bp frag-
ment) from the somatic transcriptional start site were included in the Dnmt1 promoter. Point mutation at one or more putative FLI1-binding sites in the
220-bp Dnmt1 promoter fragment reduced IL-6 (30 ng/ml) responsiveness of the Dnmt1 promoter. Mutation at all putative FLI1 sites decreased significantly
IL-6-dependent Dnmt1 promoter activation (b). Promoter activity was measured by SEAP2 reporter gene assay. Values are represented as mean S.D., and
untreated controls are set to 0 in a and to 1 in b. b depicts one representative result of total three experiments. Treated probes are referred as fold change
to nontreated control (NT); *, p 0.05; **, p 0.01; ***, p 0.001. b, represents significant differences to IL-6 treated, nonmutated Dnmt1 vector (NM,
white bar):, p 0.05;, p 0.01;, p 0.001. a, n 3; b, n 4.
FIGURE 5.Hcys-stimulated Fli1 expression is inhibited by an IL-6 Ab.After 6 days (d) of treatment, a significant up-regulation of Fli1mRNA expressionwas ob-
served at 3.6mMHcys inmediumwhen comparedwith the untreated control (Co) (a). This effect was slightly decreased after 14 days. No effect on Fli1mRNA ex-
pressionwas seen after 3 days of Hcys treatment. After 6 days of Hcys treatment, inhibition of IL-6 activity by an IL-6 Ab (4g/ml) abrogated the effect of Hcys (3.6
mM) on up-regulation of Fli1 (b). To analyze Fli1mRNA expression, RNA was isolated and analyzed by qRT-PCR. Gene expression was normalized to 18 S rRNA.
Values are represented as mean S.D.; untreated control (Co) is set to 1, and treated probes are referred to as fold change to control. *, p 0.05; **, p
0.01;, p 0.05 refers to significance to Hcys-treated probes; for all graphs n 3. Lane M refers to protein molecular weight standards.
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Hcys-mediated Up-regulation of Dnmt1 Is IL-6- and
FLI1-dependent—To demonstrate that IL-6 is involved in
Hcys-dependent up-regulation of Dnmt1, as for Fli1, we co-
treated MC3T3-E1 cells with Hcys and IL-6 antibody. As
shown in Fig. 10a, Hcys up-regulation of Dnmt1 was abro-
gated by co-treatment of the cells with an IL-6 antibody. This
demonstrates that the increase of Dnmt1 expression by Hcys
is IL-6-dependent.
Results of our experiments shown in Fig. 3c and at 3 days
suggest the involvement of a transcription factor belonging to
the E-twenty six (ETS) transcription factor family because
deletion or mutation of the GGAA sites in the Dnmt1 pro-
moter abrogated IL-6-dependent promoter activation. After 6
days of Hcys treatment, chromatin immunoprecipitation with
an antibody against FLI1 transcription factor was used to
demonstrate the interaction of this transcription factor with
the Dnmt1 promoter in vivo.
Fig. 10b clearly shows that FLI1 bound to the Dnmt1 pro-
moter sequence exhibiting three GGAA sites. This demon-
strates FLI1 occupancy on the Dnmt1 proximal promoter in
MC3T3-E1 cells. Moreover, Hcys treatment of MC3T3-E1
cells increased FLI1 binding to this Dnmt1 promoter area by
1.97-fold (p 0.05) proving involvement of FLI1 in Hcys-
mediated Dnmt1 up-regulation. These results demonstrate
that in Hcys-dependent stimulation of Dnmt1 expression in
mouse pre-osteoblasts, IL-6 as well as the transcription factor
FLI1 play a main role.
Hcys Suppressed Lox Expression by CpG Methylation—As
we have already shown before, Hcys suppresses the mRNA
expression of Lox (9). Fig. 11a demonstrates that LoxmRNA
expression was not affected after 3 days of Hcys treatment but
was significantly decreased after 6 days (1.82-fold, p 0.05)
and after 14 days (1.71-fold, p 0.05) at 3.6 mM Hcys. Analy-
sis of the Lox promoter showed a CpG-rich region ranging
from the proximal Lox promoter into the first exon (Fig. 1b),
which was used to study CpG methylation. As shown in Fig.
11b, inversely to LoxmRNA expression, Lox promoter meth-
ylation of the investigated region was significantly increased
FIGURE 6.Hcys stimulated Fli1 expression is inhibited by AG490, an in-
hibitor of JAK2 activity. After 6 days of Hcys treatment, inhibition of JAK2
by AG490 (AG) (30 M) abrogated the effect of Hcys (3.6 mM) on up-regula-
tion of Fli1 on the mRNA (a) as well as on the protein level (b and c). To ana-
lyze Fli1mRNA expression, RNA was isolated and analyzed by qRT-PCR.
Gene expression was normalized to 18 S rRNA. 30 g of protein of each
sample were fractionated by SDS-gel electrophoresis and immunoblotted.
Values are represented as mean S.D.; untreated control (Co) is set to 1,
and treated probes are referred as fold change to control. *, p 0.05;,
p 0.05 refers to significance to Hcys-treated probes; for all graphs n 3.
One representative immunoblot is shown. Lane M refers to protein molecu-
lar weight standards.
FIGURE 7.mRNA expression ofDnmt1, a gene involved in DNAmethyla-
tion, is enhanced by Hcys in MC3T3-E1 cells. As demonstrated in a, when
compared with untreated control (Co), mRNA expression of the DNAmethyl-
ation-related gene Dnmt1was significantly enhanced by 3.6 mM Hcys after
6 and 14 days (d) of treatment. Hcys-dependent up-regulation of DNMT1
was confirmed at the protein level after 6 days of treatment (b and c). To
analyze mRNA expressions, RNA was isolated and analyzed by qRT-PCR.
Gene expression was normalized to 18 S rRNA. 30 g of protein of each
sample were fractionated by SDS-gel electrophoresis and immunoblotted.
Values are represented as mean S.D.; untreated control (Co) is set to 1,
and treated probes are referred as fold change to control. *, p 0.05; ***,
p 0.001; for all graphs n 3. One representative immunoblot is shown.
Lane M refers to protein molecular weight standards.
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after 6 days (1.8-fold, p 0.05) and after 14 days (2.1-fold,
p 0.05) of treatment with Hcys; although the difference in
Hcys-mediated CpG methylation between 6 and 14 days was
not significantly different.
To prove the role of DNA methylation in Hcys-dependent
down-regulation of Lox expression, MC3T3-E1 cells were
cultured for 6 days with or without 3.6 mM Hcys in the pres-
ence or absence of 50 M zebularine, an inhibitor of DNA
CpG methylation. As shown in Fig. 11c, Hcys again attenu-
ated expression of LoxmRNA expression significantly. Zebu-
larine when added to the Hcys-treated cells significantly in-
creased Lox expression, even above the expression level of
untreated cells, thus indicating a prevalent basal CpG
methylation.
To test whether the IL-6-JAK2-FLI1 pathway was a pre-
requisite for Lox suppression, MC3T3-E1 cells were treated
for 6 days with or without Hcys and for the last 3 culture
days in the absence or presence of the JAK2 inhibitor
AG490. As shown in Fig. 12a, Hcys down-regulated the
mRNA expression of Lox, whereas AG490, having no effect
on basal expression, abolished the Hcys-dependent repres-
sion of Lox. Very similar effects were observed on the pro-
tein level by immunoblot analysis (Fig. 12, b and c). At the
protein level, again, Hcys down-regulated LOX protein ex-
pression, whereas AG490 treatment induced Lox expres-
sions when compared with control; however, only the dif-
ference between Hcys and Hcys  AG490 was statistically
significant.
DISCUSSION
Genome-wide mRNA expression analysis of Hcys-treated
MC3T3-E1 cells revealed a strong up-regulation of IL-6 and
of several genes involved in IL-6/JAK2-dependent signal
transduction pathways. The up-regulation of IL-6 by Hcys
was confirmed at the protein level by measurements with an
ELISA. The IL-6 concentrations were in the range expected to
permit the stimulation of Fli1 and Dnmt1 via JAK2.
The stimulation of IL-6 expression by Hcys in the pre-os-
teoblastic MC3T3-E1 cell line per se was an unexpected find-
ing of these experiments; it suggests that Hcys affects via IL-6
both osteoblasts, the bone-forming cells, and osteoclasts, the
bone-resorbing cells (24).
The published reports concerning the effects of IL-6 on
bone cells are conflicting (24–26). IL-6-deficient mice have
no obvious bone phenotype, but they are protected from bone
loss caused by estrogen depletion (27). In bone marrow cul-
tures from ovariectomized mice, the increased osteoclast for-
mation could be prevented by 17-estradiol or by a neutraliz-
ing IL-6-antibody (28, 29). It was also reported that IL-6
stimulates RANKL expression in osteoblasts (30), which in-
duces osteoclastogenesis. On the other hand, it was shown
that IL-6 inhibits RANKL-induced osteoclast formation and
bone resorption (31). These contradictory effects of IL-6
might be attributed to the ambivalent character of this cyto-
kine. IL-6 activates via Jak1/2 several intracellular pathways.
Activation of STAT protein pathways induces expression of
genes implicated in growth inhibition, apoptosis, and differ-
entiation, whereas activation of MAPK, protein-kinase B
(Akt), or PKC counterbalances these signals (24, 26). As we
have shown previously, Hcys weakly down-regulates cell mul-
tiplication, triggers cell differentiation (9), and favors the ex-
pression of the pro-apoptotic gene Fas (data not shown). The
FIGURE 8.mRNA expression of Hells, a co-regulator of DNAmethylation,
is enhanced by Hcys in MC3T3-E1 cells. As demonstrated in a, when com-
pared with untreated control (Co), mRNA expression of the DNAmethyla-
tion-related gene Hellswas significantly enhanced at all times measured.
Hcys-dependent up-regulation of HELLS was confirmed at the protein level
after 6 days (d) of treatment (b and c). To analyze mRNA expressions, RNA
was isolated and analyzed by qRT-PCR. Gene expression was normalized to
18 S rRNA. 30 g of protein of each sample were fractionated by SDS-gel
electrophoresis and immunoblotted. Values are represented as mean
S.D.; untreated control (Co) is set to 1, and treated probes are referred as
fold change to control. *, p 0.05; **, p 0.01; for all graphs n 3. One
representative immunoblot is shown. Lane M refers to protein molecular
weight standards.
FIGURE 9.mRNA expression ofDnmt3b, a gene involved in DNAmethyl-
ation, is enhanced by Hcys in MC3T3-E1 cells. As demonstrated, when
comparedwith untreated control (Co), mRNA expression of the DNAmethyl-
ation-related gene Dnmt3bwas significantly enhanced by 3.6 mM Hcys after
6 and 14 days (d) of treatment. To analyze mRNA expressions, RNA was iso-
lated and analyzed by qRT-PCR. Gene expression was normalized to 18 S
rRNA. Values are represented as mean S.D.; untreated control is set to 1,
and treated probes are referred as fold change to control. *, p 0.05; ***,
p 0.001; n 3.
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stimulation of Fli1 expression by IL-6, as described in this
work, was shown to be STAT3-dependent but MAPK-inde-
pendent in erythroleukemia cells (23), suggesting that Hcys-
dependent up-regulation of Fli1 and Dnmt1 in MC3T3-E1
cells depends on the STAT pathway.
Analysis of the mouse Dnmt1 promoter revealed three pu-
tative binding sites for FLI1 with identical sequence and a
structure comparable with the human promoter (19). Trunca-
tion of the promoter as well as mutation of the putative FLI1-
binding sites demonstrated that all three binding sites were
necessary for full expression. As already mentioned, IL-6 acti-
vates several intracellular signaling pathways, which can stim-
ulate transcription of DNMT1. In colon cancer cells, IL-6 was
also shown to mediate gene silencing via epigenetic DNA
methylation by DNMT1 involving STAT signaling (32). In
malignant T-lymphocytes, DNMT1 was stimulated by
STAT3, which binds to the promoter of DNMT1 (33). Simi-
larly to human erythroleukemia cells (19), in MC3T3-E1 cells
we clearly show that IL-6 stimulates Dnmt1 via FLI1. Never-
theless, we cannot fully exclude STAT3-binding sites up-
stream of the used Dnmt1 promoter fragment, which may
regulate Dnmt1 directly. All those data support our finding of
an IL-6-induced expression of Dnmt1 by Hcys, which in turn
mediates Lox down-regulation (Fig. 13).
FIGURE 10. Hcys-mediated up-regulation of Dnmt1 is IL-6- and Fli1-dependent. After 1 week of Hcys treatment, IL-6 Ab significantly abrogated the ef-
fect of Hcys on Dnmt1 expression while leaving Dnmt1mRNA expression in Hcys-untreated cells unaffected (a). Involvement of FLI1 transcription factor in
Hcys-driven Dnmt1 up-regulation was shown by chromatin immunoprecipitation analysis (ChIP) (b). After 1 week, Hcys-treated cells showed a significant
increase of FLI1 binding affinity to the selected Dnmt1 promoter sequence. mRNA expressions as well as ChIP-DNA were analyzed by qRT-PCR. Gene expres-
sion was normalized to 18 S rRNA. For ChIP quantitation, DNA signals of the FLI1-precipitated chromatin were normalized to the unprecipitated chromatin
fraction (1% of the total chromatin). Values are represented as mean S.D.; untreated control (Co) is set to 1, and treated probes are referred as fold change
to control. *, p 0.05;, p 0.01 refers to significance to Hcys-treated probes; for all graphs n 3.
FIGURE 11.Hcys affects LoxmRNA expression by promoter methylation in pre-osteoblastic MC3T3-E1 cells. After 6 and 14 days of treatment with 3.6
mM Hcys in the culture medium, a significant (p 0.05) decrease of LoxmRNA expression was observed when compared with control (Co) (a). To the con-
trary, CpGmethylation of Lox promoter and the first untranslated exon was significantly (p 0.05) increased after 6 and 14 days of treatment with 3.6 mM
Hcys (b). Addition of the CpGmethylation inhibitor zebularine (50 M) to Hcys-treated MC3T3-E1 cells (3.6 mM) abrogated the repressive effect of Hcys on
LoxmRNA expression (c). To analyze mRNA expression of Lox (a and c), RNA was isolated and analyzed by qRT-PCR. Gene expression was normalized to 18 S
rRNA. For promoter methylation (b), DNA was isolated, and the ratio of methylated to unmethylated CpGs was analyzed by MECP2 binding. Values are rep-
resented as mean S.D.; untreated controls (Co) are set to 1, and treated probes are referred as fold change to controls for *, p 0.05; **, p 0.01;,
p 0.01 refers to significance to Hcys-treated probes. For all graphs n 3.
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Epigenetic DNA methylation controls important cellular
events like apoptosis (17, 34) or cell differentiation (35). The
influence of Hcys on epigenetic CpG methylation is mainly
discussed in light of the role of Hcys as metabolite in the DNA
methylation cycle (16). As presented in this study, in pre-os-
teoblastic MC3T3-E1 cells Hcys increases the expression of
genes involved in DNA methylation, namely Dnmt1, Dnmt3b,
and Hells, but no regulation was found for the gene Dnmt3a.
Hells was suggested to play an important role in bone cells as
Hells-depleted mice develop osteopenia and osteoporosis
(36). These are interesting aspects as Hells was shown to play
a crucial role for a proper CpG methylation by recruiting
Dnmt1 and Dnmt3b to promoters (37).
According to the literature, Dnmt1 is mainly related to
maintenance of DNA global methylation, whereas Dnmt3a
and Dnmt3b are described as de novo DNAmethyltrans-
ferases (38). However, it was shown that for efficient CpG
island methylation of the gene HOXB13, a transcription factor
indispensable for vertebrate embryonic development, cooper-
ation of DNMT1 with DNMT3b is essential (39). As we have
shown here, inhibition of JAK2 eliminates Hcys-dependent
Fli1 and thus Dnmt1 stimulation and abolishes Hcys-medi-
ated Lox down-regulation. These results underline the neces-
sity of both JAK2 and Dnmt1 for Hcys-dependent Loxmethyl-
ation. Therefore, we hypothesize that besides the role of
Dnmt1 as keeper of global DNA methylation, under certain
circumstances specific DNA methylation involves Dnmt1.
As already mentioned, Hcys inhibits LOX (7) enzymatic
activity similarly to lathyrogens like -aminopropionitrile
and affects bone quality because of disturbed cross-linking
(14). As shown previously (9, 10) and as demonstrated here,
the effect of Hcys on collagen cross-link formation does not
exclusively rely on Hcys enzymatic inhibition of LOX. Besides
its function in collagen cross-linking, the N-terminal peptide
of Lox acts as a tumor suppressor. In tumors, Lox expression
is prevented by CpG methylation of the promoter as shown in
humans (40–42) and mice (34). Treatment of MC3T3-E1
cells with zebularine, an inhibitor of DNA methyltransferases,
prevented attenuation of Lox by Hcys. Methylation analysis of
the Lox promoter revealed that treatment of MC3T3-E1 cells
with Hcys increased promoter methylation of a CpG-rich re-
gion around the transcription start, which represents a com-
mon epigenetic mechanism involved in silencing of gene ex-
pression (17, 34).
In conclusion, we demonstrate that Hcys stimulates IL-6
synthesis, which could modulate osteoclast development and
differentiation via a general inflammatory response or by
direct activation resulting in increased bone resorption.
FIGURE 12.Hcys-attenuated LoxmRNA expression is abrogated by the
JAK2 inhibitor AG490. Co-treatment of MC3T3-E1 cells with Hcys (3.6 mM)
and the JAK2 inhibitor AG490 (AG) (30 M) erased the suppressive effect of
Hcys (3.6 mM) on LoxmRNA expression. Treatment of AG490 alone did not
influence Lox mRNA expression in the pre-osteoblasts (a). A similar effect
was observed when protein expression was analyzed (b and c). RNA was
isolated and analyzed by qRT-PCR. Gene expression was normalized to 18 S
rRNA. 30 g of protein of each sample were fractionated by SDS-gel elec-
trophoresis and immunoblotted. Values are represented as mean S.D.,
untreated controls (Co) are set to 1, and treated probes are referred to as
fold change to controls for *, p 0.05; **, p 0.01;, p 0.05;, p
0.01 refers to significance to Hcys-treated probes. For all graphs n 3. One
representative immunoblot is shown. Lane M refers to protein molecular
weight standards.
FIGURE 13. Schematic representation of the suggested pathway for the
down-regulation of Lox by Hcys. Hcys stimulates IL-6 expression, which in
turn activates JAK2 kinase (IL-6 as well as JAK2 kinase can be blocked by an
IL-6 Ab as well as by the inhibitor AG490, respectively), leading to an up-
regulation of the Dnmt1 transcription factor Fli1. This increases Dnmt1
expression, which provokes promoter methylation of Lox and thus its tran-
scriptional depletion (co-treatment of the cells with the DNA (cytosine-5)-
methyltransferase (Dnmt) inhibitor zebularine abrogates Hcys Lox promoter
methylation). Consequently, the post-translational collagen cross-link for-
mation is reduced. Abbreviations used are as follows: Hcys, homocysteine;
IL-6, interleukin 6; IL-6 Ab, interleukin 6 antibody; IL-6R, interleukin 6 recep-
tor; Fli1, Friend leukemia virus integration 1; Dnmt1, DNAmethyltransferase
1; Lox, lysyl oxidase; CH3, methyl group.
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Moreover, Hcys inhibits proper collagen cross-linking
biochemically by inhibiting LOX enzymatic activity, and as
demonstrated here, it attenuates Lox expression epigenetically
via IL-6, JAK2, Fli, and Dnmt1 leading to decreased bone ma-
trix quality (14). All these findings, including accelerated dif-
ferentiation of osteoblasts by Hcys (9, 10), could explain high
bone turnover in some patients with elevated Hcys serum
levels (43). This also has significant implications for other
cells and tissues. Silencing of Lox in skin and blood vessels, for
example, could reduce tissue strength. Finally, this gene acts
as a tumor suppressor in several tissues. Our findings add new
mechanistic insights to the role of Hcys as a risk factor for
bone health.
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ORIGINAL PAPER
Extra-celluar matrix suppresses expression of the apoptosis
mediator Fas by epigenetic DNA methylation
Roman Thaler • Heidrun Karlic • Silvia Spitzer •
Klaus Klaushofer • Franz Varga
 Springer Science+Business Media, LLC 2010
Abstract The extracellular matrix (ECM) of bone con-
sists mainly of collagen type I, which induces osteoblastic
differentiation and prevents apoptosis. Fas induces apop-
tosis in cells improperly adhering to ECM. Recently, it was
described that Fas expression is modulated by epigenetic
DNA methylation. Mouse MC3T3-E1 pre-osteoblastic
cells were cultured either on collagen coated or on
uncoated culture dishes for control. mRNA was isolated
and gene expression was analyzed by quantitative
RT–PCR. Furthermore, we measured global and specific
DNA methylation. Compared to controls, cells cultured on
collagen-coated dishes increased the expression of Runx2
and OCN indicating differentiation of pre-osteoblastic
cells. Additionally, collagen up-regulated cyclin-A2 and
down-regulated Fas expression suggesting increased cell
multiplication. Furthermore, the expression of Dnmt1 and
Hells, key mediators of the DNA-methylation process, was
increased. As a consequence, we demonstrate that global
DNA methylation and specific methylation of the Fas
promoter was higher in MC3T3-E1 cells cultured on col-
lagen when compared to controls. Investigation of signal
transduction pathways by mean of inhibitors suggests that
focal adhesion kinase, MAP- and Jun-kinases and AP-1 are
involved in this process. In summary, we demonstrate that
ECM prevents activation of Fas by epigenetic DNA-
methylation.
Keywords Fas expression  Extracellular matrix 
DNA methylation  Osteoblasts  Differentiation
Introduction
Bone development and homeostasis are regulated by sig-
nals that balance continuous differentiation of bone matrix-
producing cells against apoptosis and matrix removal [1]. It
is well known that cell adhesion to extracellular matrix
(ECM) mediates structural anchorage and primary survival
signals to the cell. Osteoblasts, the bone forming cells
synthesize and deposit their own ECM, which promotes
differentiation by enhancing the expression of cell type
specific genes [2, 3]. Integrins, which represent cellular
ECM anchorage proteins, in coordination with growth- and
differentiation factors, induce signal transduction cascades
important in the determination of cell proliferation, dif-
ferentiation and apoptosis [4, 5]. Cells interaction with an
adequate ECM prevents from anoikis (homelessness), a
specific form of apoptosis [6]. Among many described
pathways, Fas mediated apoptosis signaling pathway was
demonstrated to play a considerable role in this process [7].
In K-ras transformed NIH-3T3 mouse fibroblasts,
apoptosis is inhibited by epigenetic silencing of Fas mRNA
expression through DNA methyltransferase 1 (Dnmt1).
This methylation process implies 28 genes (including
MAPK1) and knockdown of any of these genes results in
failure to recruit Dnmt1 to Fas promoter preventing so CpG
methylation and allowing Fas expression [8].
In mammals, Dnmt’s mediated epigenetic DNA meth-
ylation is characterized by deoxycytidine methylation at
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position 50 of the base, whereas neighboring deoxyguano-
sines are essential resulting in specific methylation at CG
sites (CpG). Additionally, Hells (PASG, LSH), a protein
involved in chromatin remodeling, was recently shown to
associate with Dnmt1 enhancing DNA methylation [9].
DNA methylation dependent changes of chromatin status
lead to modulation of gene expressions and chromatin
stability determining differentiation, pathogenesis and
senescence of a cell. In somatic cells, Dnmt1 expression is
regulated in a cell cycle dependent manner by the tran-
scription factors Sp1 and Sp3 [10]. Furthermore, a regu-
lation of the gene by the Ras-AP1 signaling pathway was
reported for the mouse P19 teratocarcinoma cell line
[11, 12].
MC3T3-E1 cells represent a pre-osteoblastic cell line,
which differentiates from a pre-osteoblastic phenotype into
mature osteoblasts. During the differentiation process
expression of osteocalcin (OCN) and its regulator Runx2,
two well-known markers of osteoblastic differentiation,
increase. Those features make this cell line an excellent
model system to study osteoblastic growth, differentiation
and apoptosis [2, 13] [14, 15].
In this study we investigated the consequences of
osteoblastic adherence on collagen type I, the major
organic component of bone ECM, on mRNA expression of
the pro apoptotic gene Fas, the proliferation associated
gene cyclin A2 and the differentiation related genes Runx2
and OCN. Furthermore, we investigated by which mecha-
nism collagen regulates Fas expression. Our results dem-
onstrate that collagen type I repress Fas expression by
promoter CpG methylation showing that epigenetic
mechanisms are involved in ECM mediated signaling in
osteoblasts.
Experimental procedures
Cell culture and collagen coating
MC3T3-E1 cells, a clonal preosteoblastic cell line derived
from newborn mouse calvaria (kindly donated by
Dr. Kumegawa, Meikai University, Department of Oral
Anatomy, Sakado, Japan), were cultured in humidified air
under 5% CO2 at 37C in alpha-minimum essential med-
ium (a-MEM; Biochrom, Berlin, Germany) supplemented
with 5% fetal calf serum (Biochrom), 50 lg/ml ascorbic
acid (Sigma), and 10 lg/ml gentamycin (Sigma). For
propagation, cells were sub-cultured twice a week using
0.001% pronase E (Roche) and 0.02% EDTA in Ca2?- and
Mg2?- free phosphate-buffered saline (PBS) before
achieving confluence. To prevent a potential phenotypic
drift during repeated sub-cultures the cells were not used
more than 4 weeks after thawing.
For experiments the cells were seeded in culture dishes
coated with or without rat-tail collagen at a density of
2,000/cm2 and cultured for the indicated time with medium
changes twice a week. For collagen coating, cell culture
dishes were coated at a concentration of 5 lg/cm2 as
suggested by the supplier (BD Biosciences). Cells cultured
on collagen-coated dishes were confluent after 4–5 days
while control cells needed 6–7 days of culture for conflu-
ence. However, seeding at 2,000 compared to 20,000
cells/cm2 did not influence Dnmt1 expression significantly
(R. Thaler, unpublished observations).
Treatment with inhibitors of signal transduction was
performed with the focal adhesion kinase inhibitor (FAK)
genistein [16] (10 lM, Sigma), the selective MAP-/ER-
kinase inhibitor PD98059 [17] (10 lM, Promega) and the
AP1 inhibitor resveratrol [18] (40 lM, Sigma). In these
experiments, inhibitors were added to the cells 30 min
before seeding. Genistein and PD98059 were solved in
DMSO as 1,000-fold stock-solution to prevent influence on
gene expression (Thaler, R et al. in preparation) and res-
veratrol was dissolved in ethanol.
Isolation of nucleic acids and expression analysis
by QRT-PCR
DNA and RNA were extracted using a DNA/RNA Isola-
tion Kit (Qiagen). cDNA was synthesized from about
0.5 lg RNA using the 1st Strand cDNA Synthesis Kit as
described by the supplier (Roche). The obtained cDNA was
subjected to PCR amplification with a real-time cycler
using FastStart SYBR Master Mix (Roche) for the genes
Dnmt1, Hells, c-Fos, c-Jun, Fas and Cycline A2. SYBR-
Green PCR was started with 10 min of an initial denatur-
ation step at 95C and then continued with 45 cycles
consisting of 30 s denaturation at 95C, 30 s annealing at
primer specific temperatures and extension at 72C. For
amplification of Runx2 and OCN (Bglap2) we used
TaqMan gene expression probes (Mm00501578_m1 and
X04142-EX2, respectively, Applied Biosystems) and for
normalization we used the 18S RNA TaqMan probe
(4319413E, Applied Biosystems). All reactions were per-
formend in TaqMan Gene Expression Master Mix (Applied
Biosystems) with an initial denaturation at 95C for 10 min
followed by 45 cycles alternating 60C for 30 s and 95C
for 10 s. All PCRs were performed in triplicate. Expression
was evaluated using the comparative quantization method
[19].
Global methylation
MC3T3-E1 cells seeded at a density of 2,000/cm2 and
cultured for 4 days on collagen type I coated dishes or
uncoated control dishes, were washed twice with PBS,
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detached with 0.02% Pronase in PBS and then collected by
centrifugation (1,400 rpm). Thereafter, DNA and RNA
were isolated from about 5 9 105 cells with a DNA/RNA
isolation Kit (Quiagen). Global methylation was addressed
[20] from 100 ng DNA digested in multi core buffer
(Promega) with 5 U MspI or HpaII or incubated without
enzyme (background) for 3 h at 37C in a total volume of
30 ll. The restriction of the DNA was followed by an end-
fill reaction where to the restriction digest 20 ll of a
mixture containing 0.1 lM Biotin-11-dCTP and 0.1 lM
Biotin-11-dGTP (Perkin Elmer, Boston, MA) and 0.5 U
Klenow-fragment of DNA-polymerase III (Promega) in
500 mM Tris–HCl, pH 7.2, 100 mM MgSO4 and 1 mM
dithiothreitol have been added and incubated at room
temperature for half an hour. Thereafter, the reaction was
transferred into multi-well plates (Optiplate, Beckman) and
100 ll of Reacti-BindTM DNA Coating Solution (Pierce,
Rockford, IL) was added to each well and incubated over
night at room temperature. On the next day, the wells were
washed once with TBS (10 mM Tris–HCl pH 8.0, 150 mM
NaCl). After a blocking step with 1% blocking solution
(Roche) in TBS for 1 h, a solution of 50 ng/ll streptavidin-
horse radish peroxidase conjugate (Promega) in TBS was
added and incubated for one further hour at room tem-
perature. Thereafter, the wells were washed three times
with TBS containing 0.5% Tween 20 and two times with
water. 100 ll of the chemo-luminescence substrate was
added to each well and the light emission was measured in
a top-counter (Packard Instruments).
Specific promoter methylation
To analyze Fas promoter methylation, two appropriate
fragments of the targeted Fas region were generated by
digestion of 1 lg of genomic DNA with 40 U of the CpG-
methylation insensitive restriction enzyme MboII (New
England Biolabs) for 20 min from cells cultured for 4 days
on collagen type I coated dishes or uncoated control dishes.
Subsequently, the enzyme was heat inactivated at 65C for
20 min. The two regions were selected according to litera-
ture [8]. As shown in Fig. 1, fragment 1 had 627 bp and
contains 25 CpG-sites. It includes 130 bp of the proximal
promoter region of Fas, the short first exon (79 bp) with the
coding region for the first 10 amino acids (30 bp), and
455 bp of the first intron, which is 16,380 bp long. The
second fragment (fragment 2) with 863 bp includes 15 CpGs
and starts at -2,800 bp, counted from the transcription start.
Although both fragments contain an accumulation of CpG
sites, it does not meet the criteria of a CpG-island (Fig. 1).
After MboII digestion, DNA was purified using a commer-
cially available PCR clean-up Kit following the supplier’s
instructions. In the next step methylated DNA fragments
were captured with the ‘‘MetylMiner Methylated DNA
Enrichment Kit’’ (Invitrogen) following the supplier’s
instructions. In brief, methylated DNA was captured by
methyl blinding protein 2 (MBD2) coupled to magnetic
beads and subsequently separated from the unmethylated
DNA fraction. Methylated DNA was eluted from the
MBD2-beads with 200 ll of 2 M NaCl solution as single
fraction independent from the CpG methylation density and
concentrated by ethanol precipitation. Finally, the mean
methylation status of the fragments was determined by
amplifying the fragments by quantitative real-time PCR.
Amplification ratios of the bound (methylated) DNA frac-
tion to unbound (unmethylated) DNA fraction were calcu-
lated (for primer design see Table 1).
Statistical analysis
Statistical analyses were performed using either ANOVA
or Student’s t-test using Prism 4.03 (GraphPad Software,
San Diego, CA). P B 0.05 was considered as significant.
For each experiment, the triplicate results of the RT–qPCR
were averaged and this mean value was treated as a single
statistical unit. The data of the triplicate experiments are
presented as means ± standard deviation (SD).
Results
Extracellular collagen influences expression of genes
related to osteoblastic differentiation, proliferation, and
apoptosis of MC3T3-E1 pre-osteoblasts
MC3T3-E1 cells were seeded either on rat-tail collagen or
on normal culture dishes (control) and cultured for 1 and
4 days. On day 1 there was a low expression of the mRNA
of both Runx2 and OCN and no significant difference
between control and collagen seeded cultures was
observed. On day 4 however, there was a significant
stimulation of Runx2 (1.39 ± 0.10-fold, Fig. 2a) as well as
OCN (1.63 ± 0.03-fold, Fig. 2b). To address whether
collagen influences cell multiplication, mRNA expression
of cyclin A2 as proliferation marker and expression of the
apoptosis related Fas was measured. In collagen seeded
cells, Cyclin A2 was up regulated on day 1 and day 4
(4.8 ± 0.28-fold, Fig. 2c) and as Fig. 2d shows Fas was
down regulated on both, day 1 (3.03 ± 0.02-fold) and day
4 (2.70 ± 0.01-fold) suggesting reduced apoptosis on
collagen covered culture dishes.
Down regulation of the apoptosis related gene Fas
by collagen is due to DNA methylation
As demonstrated above, seeding of osteoblasts on collagen
inhibits the expression of the apoptosis related gene Fas.
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Fas mRNA expression was demonstrated before to be
regulated by CpG methylation of its promoter by Dnmt1
[8]. Therefore, two regions in the Fas promoter were
studied (Fig. 1); one starting at -2,800 bp and the other
located near the transcription start [8]. In the region near
the transcription start (Fig. 1b, 25 CpGs) CpG methylation
was significantly increased (6.53 ± 1.03-fold, Fig. 3a)
after 4 days of culture in collagen-seeded osteoblasts when
compared to control cultures. A similar situation was found
with the second fragment (Fig. 1c, 14 CpGs) where the
stimulation of methylation was 2.20 ± 0.09 (Fig. 3b) when
compared to control cultures.
Collagen up regulates Dnmt1 and Hells expression
in MC3T3-E1 osteoblastic cells
As we found that the collagen dependent inhibition of Fas
expression is due to Fas promoter hypermethylation,
mRNA expression of Dnmt1 was analyzed. After seeding
of MC3T3-E1 cells in control cultures and on rat-tail col-
lagen, RNA was isolated at different times (2, 4, 6 h, 1, 2, 4
and 8 days). During the first 6 h of culture, expression of
Dnmt1 changed neither in control- nor in collagen-seeded
cultures. After 1 day of culture, in both, control cultures as
well as in cultures seeded on collagen, a significant
increase in Dnmt1 expression could be observed (Fig. 4).
However, in collagen-seeded cells the increase was
2.18 ± 0.02-fold stronger than in control cultures. More-
over, the up regulation of Dnmt1 disappeared in control
cultures after 2 days whereby in collagen-seeded cells the
effect was highest at day 2 (5.88 ± 0.13-fold) and still
observable after 8 days. At days 2, 4 and 8 the differences
were statistically highly significant (Fig. 4). To show that
ECM produced by MC3T3-E1 cells also has the potential
to regulate expression of Dnmt1, we prepared ECM by
growing MC3T3-E1 cells for 8 days and removed living
Fig. 1 Fas genomic structure with the first exon (79 bp) and a small
part of the first intron (921 of 16,380 bp). a Schematic diagram
depicting the exon 1, the part of intron 1 and the location of the two
fragments used for methylation analysis. b Schematic diagram of
fragment 1 depicting the location of the Exon 1 with the untranslated
region (open box) and the coding region (black arrow). Indicated as
black boxes are the forward (F1fw) and the reverse (F1rv) primers
used for amplification of the DNA after the ‘‘MetylMiner’’ assay. The
vertical bars above the horizontal line of the gene indicate the 25
CpGs of the region. c Fragment 2 with the location of the forward
(F1fw) and the reverse (F1rv) primers as black boxes. Again, the
vertical bars indicate the 14 CpGs of this region. The Mbo II
restriction sites are indicated with M and the numbers below the gene-
line denote the distance to the transcription start (TS)
Table 1 QRT-PCR primer for mRNA expression and Fas CpG methylation with Sybr Green
Gene Forward primer (50–30) Reverse primer (50–30) Tm (C)
Dnmt1 ACCGCTTCTACTTCCTCGAGGCCTA GTTGCAGTCCTCTGTGAACACTGTGG 62
Hells TGAGGATGAAAGCTCTTCCACT ACATTTCCGAACTGGGTCAAAA 62
Fas TATCAAGGAGGCCCATTTTGC TGTTTCCACTTCTAAACCATGCT 64
Ccna2 ACATTCACACGTACCTTAGGGA CATAGCAGCCGTGCCTACA 62
c-Fos CGGGTTTCAACGCCGACTA TTGGCACTAGAGACGGACAGA 63
c-Jun CCTTCTACGACGATGCCCTC GGTTCAAGGTCATGCTCTGTTT 63
Primer for Fas CpG methylation analysis
Fragment 1 CATACCCACAGGCAGTCTAGA CAGCCCAGAGTAACTCACTTC 62
Fragment 2 GAAGTAGAAACAGAAGCTGAG TTGCTACATCCCAACTGTAAC 62
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cells by detergent [21]. Figure 5 demonstrates that
MC3T3-E1 cells seeded and cultured on native ECM,
which means ECM produced by MC3T3-E1 at previous
cultures, increased the Dnmt1 mRNA levels as well.
Hells was recently described to be involved in DNA
methylation as enhancer of the DNA methylation process
[9]. Different to Dmnt1 (Fig. 4), Hells was not up regulated
after 1 day of culture on collagen but on day 4 there was a
significant up-regulation of Hells mRNA expression com-
pared to control as well to control and collagen on day one
(3.5-fold, Fig. 6).
Effect of collagen on global DNA methylation
The up regulation of Dnmt1 by collagen suggested a general
effect on DNA methylation. To this end we used a recently
published assay based on the sensitivity of the HpaII
restriction enzyme to methylated CpGs compared to the
insensitivity of MspI to cut such restriction sites. Figure 7
clearly demonstrates, that after 4 days of culture DNA global
methylation was significantly lower in control cultures
compared to collagen seeded cultures (2.38 ± 0.32-fold).
Collagen stimulation of Dnmt1 expression involves
FAK/MAP-kinase/AP1-pathway
Using genistein a naturally occurring inhibitor of FAK
phosphorylation [22] the expression of Dnmt1 was down
regulated in collagen-seeded cultures compared to control
(Fig 8, Gen labeled bar). A similar behavior was found when
cells were treated with PD98059 a potent and selective
inhibitor of the MAP-/ER-kinase. Figure 8 (PD labeled bar)
clearly shows that at the used concentration, Dnmt1 mRNA
expression was similarly attenuated as with genistein. Sig-
nals of the MAP-kinase pathway usually regulates AP1
activity that could be inhibited by resveratrol as described
before [23]. While in control cultures Dnmt1 mRNA
expression was not affected by resveratrol treatment, this
inhibitor clearly abolished the up regulation of Dnmt1 in
collagen-seeded cultures (Fig. 9). mRNA down regulation
of c-Jun as well as of c-Fos, the genes coding for the proteins
of AP-1, could be observed in dependence of resveratrol in
collagen seeded as well as in control cultures (Fig. 10).
Attenuation of collagen-induced Dnmt1 treatment of the
cells with CHX, an inhibitor of protein-synthesis suggests
Fig. 2 Extracellular collagen influences expression of genes related
to osteoblastic differentiation, proliferation, and apoptosis of MC3T3-
E1 pre-osteoblasts. After 4 days of culture MC3T3-E1 cells cultured
on collagen express higher levels of Runx2 (a) and OCN (b) mRNA
compared to control cultures indicating progress in differentiation.
MC3T3-E1 cells cultured on collagen, express higher levels of
mRNA for cyclin A2 (c), a marker for proliferation, and lower levels
of Fas (d), a marker of apoptosis. MC3T3-E1 were either seeded on
rat-tail coated (Collagen) or on uncoated (Control) culture dishes and
cultured for 1 and 4 days. RNA was isolated and analyzed by
QRT–PCR. The specific gene expression was normalized to 18S
rRNA. The bars represent the mean ± SD. * P B 0.05; ** P B 0.01;
N = 3; *** P B 0.001; N = 3
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that de-novo protein synthesis is involved in collagen-med-
iated up regulation of Dnmt1 (Fig. 11).
Discussion
Adhesion to an appropriate ECM prevents cells from
apoptosis. This well established process involves several
biochemical signal transduction pathways [24, 25]. ECM
Fig. 3 Down-regulation of the apoptosis related gene Fas by collagen
is due to DNA methylation. Methylation status of two CpG rich
region of the Fas-promoter depended whether MC3T3-E1 cells are
cultured on collagen-coated or on uncoated culture plates. MC3T3-E1
were either seeded on rat-tail coated or on uncoated (Control) culture
dishes and cultured for 4 days. Thereafter, DNA was isolated and the
ratio of methylated to unmethylated CpGs at the promoter positions
-30 bp (a) or -2,600 bp (b) from the transcription start were
calculated. The bars represent the mean ± SD. ***P B 0.001; N = 3
Fig. 4 Collagen up-regulates Dnmt1 expression in MC3T3-E1
osteoblastic cells. Time course of Dnmt1 expression of MC3T3-E1
cells cultured either on collagen covered or normal culture dishes.
MC3T3-E1 were either seeded on rat-tail coated (Collagen) or on
uncoated (Control) culture dishes and cultured for the indicated time.
Thereafter, RNA was isolated and analyzed by QRT–PCR. The
specific gene expression was normalized to 18S rRNA. The symbols
represent the mean ± SD. *** P B 0.001; N = 3
Fig. 5 ECM synthesized by MC3T3-E1 cells increased Dnmt1
expression of MC3T3-E1 cells compared to cells cultured on normal
culture dishes. MC3T3-E1 cultures were cultured 1 week to produce
ECM. After removing living cell, fresh MC3T3-E1 were seeded onto
this matrix and cultured for another week. Thereafter, RNA was
isolated and analyzed by QRT-PCR. The specific gene expression was
normalized to 18S rRNA. MC3T3-E1 cells grown on uncoated culture
dishes served as controls (Co). The symbols represent the mean ±
SD. **P B 0.01; N = 3
Fig. 6 Collagen up-regulates Hells expression in MC3T3-E1 osteo-
blastic cells on day 4. MC3T3-E1 were either seeded on rat-tail
coated (Collagen) or on uncoated (Control) culture dishes and
cultured for the indicated time. Thereafter, RNA was isolated and
analyzed by QRT–PCR. The specific gene expression was normalized
to 18S rRNA. The symbols represent the mean ± SD. * P B 0.05;
N = 3
Fig. 7 MC3T3-E1 cells cultured on collagen had increased global
CpG-methylation of DNA compared to cells cultured on uncoated
culture plates. MC3T3-E1 cells were either seeded on rat-tail coated
or on uncoated culture dishes and cultured for 4 days. Thereafter,
DNA was isolated and the ratio of methylated to unmethylated CpGs
was compared. The bars represent the mean ± SD. ** P B 0.01;
N = 3
Apoptosis
123
sends signals to proceed through cell cycle checkpoints, to
either proliferate, differentiate or to go into anoikis. These
signals protrude from growth factor receptors and ECM
receptors, the integrins; thus, a coordinate action of both
determine cells fate [26].
Fas is a member of the TNF-receptor super family and
play a central role in the physiological regulation of pro-
grammed cell death. The involvement of Fas in anoikis is
well documented, however, the mechanism is still unclear
[7]. Physiologically, during development and maintenance
of tissue homeostasis, Fas up regulation occurs in case of
detachment of cells from their ECM. Pathologically, as for
metastatic tumor cells, down regulation of genes like Fas
enable these cells to circumvent anoikis and so to adhere to
an un-physiological substrate [27]. In such metastatic
processes, Ras was shown to play an important role in
Dnmt1 mediated Fas silencing by promoter methylation
[8]. In the present work we demonstrate that seeding of pre-
osteoblastic MC3T3-E1 cells on collagen type I coated
dishes, compared to uncoated, repressed Fas expression
and increased Dnmt1 expression; this suggested a similar
mechanism in Fas regulation.
Analysis of the methylation status of two CpG rich
regions located around the transcription start that are hy-
permethylated in K-ras transformed NIH 3T3 cells [8]
revealed a higher methylation status in collagen-seeded
cells. These data suggests that collagen either increased
methylation of that CpGs or prevented it from demethyla-
tion, at least. The latter consideration is supported by
Fig. 8 Specific inhibitors of the MAP-kinase-pathway inhibited
Dnmt1 expression of MC3T3-E1 cells cultured on collagen compared
to control cultures. MC3T3-E1 were either seeded on rat-tail coated
(Col) or on uncoated (Con) culture dishes and cultured for 1 day with
either 10 lM Genistein (Gen) or 10 lM PD98059 (PD). Both
inhibitors down regulated the expression of Dnmt1 in MC3T3-E1
cells, when cultured on collagen. RNA was isolated and analyzed by
QRT-PCR. The specific gene expression was normalized to 18S
rRNA. The bars represent the mean ± SD. ?? P B 0.01 Col versus
Con; ## P B 0.01 Col?Gen, Col?PD versus Con; *** P B 0.001
Col?Gen, Col?PD versus Col; Gen versus PD n.s.; N = 3
Fig. 9 Resveratrol inhibited Dnmt1 expression of MC3T3-E1 cells
cultured on collagen compared to control cultures. MC3T3-E1 were
either seeded on rat-tail (Col) coated or on uncoated (Con) culture
dishes and cultured for 1 day. While resveratrol (Res) did not
influence basal expression of Dnmt1 it strongly inhibited the
collagen-induced expression. RNA was isolated and analyzed by
QRT-PCR. The specific gene expression was normalized to 18S
rRNA. The bars represent the mean ± SD. *** P B 0.001 collagen-
grown versus the other cultures; N = 3
Fig. 10 MC3T3-E1 cells cultured on collagen-coated culture dishes
express higher levels of the genes of the AP1 complex compared to
cells cultured on normal dishes. Both basal as well as collagen
stimulated expression was down regulated by resveratrol MC3T3-E1
were either seeded on rat-tail coated or on uncoated culture dishes and
cultured for 1 day and treated without or with 40 lM resveratrol
(Res). RNA was isolated and analyzed by QRT-PCR. The specific
gene expression was normalized to 18S rRNA. The bars represent the
mean ± SD. All differences were highly significant (P B 0.001)
different, except Res versus Res?Col where it was P B 0.05. N = 3
Fig. 11 Cycloheximid (CHX) inhibited Dnmt1 expression of
MC3T3-E1 cells cultured on collagen compared to control cultures.
MC3T3-E1 were either seeded on rat-tail (Col) coated or on uncoated
(Col) culture dishes and cultured for 1 day without or with 10 lg/ml
CHX. While CHX did not influence basal expression of Dnmt1, it
strongly inhibited the collagen-induced expression. RNA was isolated
and analyzed by QRT-PCR. The specific gene expression was
normalized to 18S rRNA. The bars represent the mean ± SD.
*** P B 0.001 Col versus Con and Col?CHX; ?? P B 0.01
Col?CHX versus Con and Col versus CHX. N = 3
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findings that global methylation had been decreased during
culture on uncoated culture dishes for 2 weeks and correlates
with Fas mRNA expression (Thaler et al. in preparation).
Although the 50-region as well as the first exon (79 bp) and
the first intron (16,380 bp) are CpG rich, they do not contain
CpG-islands when recent published criteria are applied [28].
An unmethylated core region of about 1,000 bp centered at
the transcriptional start site was recently reported to be
requisite for active transcription [29]; this mean that meth-
ylation of this region will diminish transcription as found in
our experiments. As already mentioned the large first intron
(16,380 bp) is also rich in CpG. In is feasible that methylated
CpG in this intron could also contribute to gene silencing as
recently demonstrated for the integrin collagen receptor
locus [30] and the zeta-chain (TCR) associated protein
kinase ZAP70 gene [31].
The presented finding can be considered as an epigenetic
physiological process, which avoids anoikis of cells.
Moreover, the presented results show DNA methylation as
a collagen regulated cellular process. Therefore, as colla-
gen adhesion of osteoblasts is known to trigger cell mul-
tiplication and as mRNA expression of the proliferation
marker cyclin A2, which promotes cell cycle at G1-S and
G2-M stage, was described to be enhanced by CpG
methylation at two repressor binding sites in its promoter
[32], expression and CpG methylation of this gene was
analyzed. Although we found a stimulation of cyclin A2
mRNA expression, no changes of the methylation patterns
in the promoter were found (data not shown). Further, up
regulation of cyclin D1 (data not shown) and down regu-
lation of the cell cycle inhibitor p19-INK4D (data not
shown) underline the role of collagen for cell fate decisions
in osteoblasts. A further aspect of ECM mediated cell
surveillance includes regulation of cell differentiation.
Extra cellular collagen type I differentiates mesenchymal
stem cells [5] and the results presented in this paper con-
firm the collagen mediated differentiation of pre-osteo-
blasts [33] as demonstrated by stimulated expression of
Runx2 and OCN, both well described proteins of the dif-
ferentiated osteoblastic phenotype [34, 35].
Starting from the globally low methylated stem cell,
ongoing cell differentiation implies epigenetic reprogram-
ming [36, 37]. The delicate organization of DNA methyla-
tion and chromatin status regulates the normal cellular
homeostasis of gene expression patterns and confers stability
to the genome [38, 39]. Collagen dependent maintenance of
global DNA-methylation may additionally contribute to
chromatin organization and stability, consolidating the
adopted phenotype during the differentiation process. To
what extend collagen’s influence on DNA methylation
affects differentiation of osteoblasts cannot be answered yet.
Using inhibitors of signal transduction pathways and
following KEGG PATHWAY database [40] we draw a
scheme how ECM could signal to Dnmt1 effecting DNA
methylation (Fig. 12). Resveratrol, an inhibitor of AP1
activity [23] attenuated the mRNA expression of Dnmt1 in
collagen seeded cells suggesting the involvement of this
protein-complex. This is in line with recent reports
describing a stimulation of Dnmt1 mRNA transcription by
over expressing cJun, a component of the AP1 complex.
This effect was abrogated by a deletion of the AP1
response elements in the Dnmt1 promoter demonstrating
that Dnmt1 is regulated via a Ras/Jun signaling pathway
[11, 12]. In addition, for the collagen dependent mainte-
nance of DNA methylation in osteoblasts, our experiments
suggest the involvement of the focal adhesion kinase and of
the MAP-kinase pathway, as demonstrated for Dnmt1
dependent Fas methylation in Ras transformed fibroblasts
[8]. Interestingly, for fibroblasts only the ECM component
fibronectin but not collagen sends a survival signal via
focal adhesion kinase to cJun amino-terminal kinase (JNK)
even under serum free conditions. However, the involve-
ment of JNK in survivals signaling is discussed contro-
versial and seems to be cell type specific, especially
because FAK engages multiple pathways for survival of
fibroblasts and endothelial cells [41]. Our results suggest
that in osteoblasts both pathways are needed to stimulate
Dnmt1 expression for epigenetic silencing of the pro-
apoptotic gene Fas triggering cell survival, although, the
precise mechanism has still to be clarified.
Attenuation of the collagen effect on Dnmt1 expression
by genistein and resveratrol, which represent the main
flavonoid present in soy and a phytoalexin present in red
grapes, respectively, may imply consequences in vivo. For
genistein and for other nutritional factors as well as for
Fig. 12 Schematic representation of the suggested pathway for
regulation of Dnmt1 by the ECM. The ECM activates via integrins
the focal adhesion kinase, which itself activates both pathways the
Jun-Kinase and the MAP-Kinase pathway leading to increased AP-1
transcription. The indicated block by CHX means that translation is a
prerequisite for activation of Dnmt1 transcription by AP1. Abbrevi-
ations: Int, integrins; FAK, focal adhesion kinase; MAPK, mitogen
activated protein kinase; Gen, genistein; Res, resveratrol; CHX,
cycloheximid
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nutritional habits interference with epigenetic regulation of
gene expression was demonstrated [42–44]. Therefore, we
speculate that nutritional factors may influence bone
development and homeostasis by the involvement of epi-
genetic mechanisms.
Signaling by integrins gain much attraction in bone
research as they are discussed as transducer of mechanical
forces, which is fairly important in the bone remodeling
process, where the osteoblasts construct a matrix in line with
the applied forces to the bone. Cyclic loading on bone cells
will result in both increased proliferation but also in
enhanced differentiation. It is exciting to speculate that
integrins, which also control cell-division axis at mitosis,
may regulate CpG-methylation of DNA during DNA syn-
thesis in the S phase of the cell cycle. Attachment sites of
interphase cells connect the cytoskeleton via integrins to the
ECM. During mitosis when the cell rounds up the cell
remains attached to the substratum through retraction fibers;
thus the ECM controls the cells during the whole cell cycle
[26]. This is especially important for bone cells because
external forces will direct via ECM the orientation of the
daughter cells [45]; not properly oriented cells will not gain
the methylation signal for silencing Fas and will, therefore,
apoptose. Therefore, we assume that integrins play a role in
initiating the pathway leading from collagen to DNA meth-
ylation. However, if and at which extent and under which
circumstances this may occur remains to be clarified.
In summary, we demonstrate that adhered osteoblasts on
collagen type I repress mRNA expression of the pro-apop-
totic gene Fas by preservation of CpG methylation of its
promoter. This relies on a collagen dependent up regulation
of Dnmt1 and may play an important role for osteoblasts in
avoiding anoikis by adhesion to an adequate ECM. Fur-
thermore, increase in expression of proliferation and differ-
entiation markers underline cell fate decisions directed by
collagen. Finally, maintenance of DNA global methylation
by collagen may stabilize chromatin and homeostasis of the
differentiated phenotype. In conclusion, we demonstrate
epigenetic imprinting of survival signals coming from ECM
leading to increased tissue formation and differentiation.
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6. Discussion  
 
Lathyrogens like bAPN and the metabolite hcys affect cross-linking of collagen and 
with it the quality of bone in animal models. Aim of the studies was to get insights into 
molecular mechanisms of the lathyrogens actions. The data demonstrate that both 
compounds influence osteoblastic proliferation and differentiation and hinder a stable 
bone matrix formation via inhibition of the collagen cross-linker LOX on the enzymatic 
level as well as by down-regulation of its mRNA expression. Investigating the 
mechanisms, we could elucidate the pathway by which hcys down-regulates LOX 
expression and demonstrate that beside the discussed function of hcys as methyl 
carrier in DNA methylation, it also influences the expression of Dnmts itself leading to 
epigenetic methylation of Lox promoter in osteoblasts. Furthermore, we revealed a 
new mechanism contributing to osteoblast proliferation and differentiation on collagen 
type I containing ECM. Here, collagen type I suppresses via Dnmt1 dependent 
promoter methylation the expression of the pro-apoptotic gene Fas thus 
guaranteeing osteoblastic survival and proliferation on an adequate ECM.  
The lathyrogenic effect of bAPN was extensively described in the past (1-4, 6), 
however, the role of hcys as lathyrogen is not as clear as for bAPN. Thus, the one 
purpose was to directly compare the effect of bAPN and hcys on collagen cross-links 
and additionally on mRNA expression level of genes involved in post-translational 
modification of collagen cross-linking in pre-osteoblasts (105) thus expanding 
previous studies (6). Pyr/divalent cross-link ratio analysis by FTIR showed that both 
bAPN and hcys provoked a dose-dependent increase of the ratio indicating a 
reduction of LOX activity. Furthermore, similar results were observed in a human 
study which found an association between plasma hcys levels and collagen cross-
link ratio (72). Thus, it can be concluded that regarding the lathyrogenic activity of 
hcys and bAPN, both compounds act in a comparable manner. Interestingly, both 
compounds regulate mRNA expression of important osteoblastic genes. Thus, the 
central osteoblastic transcription factor Runx2 was up regulated and as shown by 
qPCR, genes involved in collagen cross-linking like Plod2 and Lox were down 
regulated by both compounds after 1 week at a concentration of 4 mM in medium. 
This indicates that both lathyrogens disrupt the formation of a physiological ECM in 
bone but concomitantly induce osteoblastic differentiation and bone matrix 
mineralization as shown by the increased ALP levels. This may be a further patho-
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physiological effect induced by the two lathyrogens. However, if the effect of both 
compounds is compared at the level of mRNA expression of modulators of Runx2 
activity or further genes related to the osteoblastic phenotype, two different effects 
are observed. Thus, as seen by gene array analysis, the mRNA expressions of 
several genes interacting with Runx2 activity (Aes, Myst3, Myst4, Stat1, Tle2 and 
others) (119) were up-regulated by hcys but not by bAPN suggesting a distinct and 
environmental dependent effect of hcys on osteoblastic differentiation. Furthermore, 
a general evaluation of genome wide gene expression revealed that only a small part 
of genes is co-regulated by both compounds; 5.5-fold more genes are down- and 
3.8-fold more genes are up regulated by hcys compared to bAPN. This demonstrates 
the divergent genome wide effects on mRNA expression between hcys and bAPN. 
As mentioned above, both compounds not only inhibited enzymatically collagen 
cross-link formation, but also down-regulated the mRNA expression of Lox and of 
other genes involved in post-translational collagen cross-link formation such as 
Plod1, Plod2, P4ha1 and P4ha2 (120). However, generally a stronger effect was 
seen by hcys treatment.  
Lathyrogens are defined by their enzymatic inhibition of the enzyme LOX (5). The 
attenuation of LOX via down-regulation of its expression by hcys in osteoblasts 
represents a new aspect; furthermore compared to bAPN, hcys plays clinically a 
more relevant role. Thus, we started to investigate the cellular mechanisms directing 
down regulation of Lox expression by hcys. In this context first suggestions were 
given by analysis of genome wide mRNA expression of MC3T3-E1 cells treated one 
week with hcys with Affymetrix GeneChip technique. This method allows the 
observation of an effect of a substance on the expression of selected genes involved 
in different pathways and therefore permits first deductions of possible signaling 
pathways activated by the specific compound analyzed. Intense gene array analysis 
revealed a strong hcys dependent up-regulation of IL-6 and of several genes 
involved in IL-6/JAK2 dependent signal transduction pathways. The stimulation of IL-
6 expression by hcys in the pre-osteoblastic MC3T3-E1 cell-line per se was an 
unexpected and intriguing finding of these experiments: it suggests that hcys affects 
via IL-6 both, osteoblasts the bone forming cells as well as osteoclasts, the bone 
resorbing cells. Osteoclasts are large multinucleate, macrophage derived cells and in 
various cell cultures it was shown that IL-6 enhances osteoclast formation (121). For 
osteoclast maturation the production of soluble factors by osteoblasts as well as tight 
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cell-cell interactions with osteoblastic or stromal cells are needed (122). Concerning 
cell-cell contacts between osteoblasts and osteoclasts, the interaction between the 
tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11, RANKL) and the 
osteoclastic tumor necrosis factor receptor superfamily, member 11a, (TNFRSF11A, 
RANK) was found to be the major mechanism implicated in osteoclast differentiation 
and maturation (122). IL-6 dependent stimulation of RANKL expression was shown in 
osteoblasts (123) thus inducing osteoclastogenesis. In addition, treatment of bone 
marrow cells from ovariectomized mice with IL-6 antibody prevented enhanced 
osteoclast formation (124, 125). However, recent publications suggested that IL-6 
has an inhibitory effect on RANKL induced osteoclast formation and bone resorption 
(121, 125). Furthermore, IL-6 knockout mice do not show an obvious bone 
phenotype (126), showing that the published reports concerning the effects of IL-6 on 
bone cells are conflicting. These contradictory effects of IL-6 might be due to the 
ambivalent character of this cytokine and attributed to the environmental influences 
which result in activation via Jak1/2 of several different intracellular pathways (121). 
As mentioned above, we suggest that hcys dependent stimulation of IL-6 expression 
activates via Jak2 the STAT signaling pathways which induce the expression of 
genes involved in growth inhibition, apoptosis and differentiation as we have 
observed that hcys affects cell multiplication and cell differentiation and favors the 
expression of the pro-apoptotic gene Fas. Thus, in cases of chronically elevated hcys 
serum levels, besides the inhibitory effect of hcys on the generation of a stable bone 
matrix formation by enzymatic and transcriptional inhibition of LOX, hcys may further 
affect bone homeostasis by modulation of bone mineralization, osteoblastic 
differentiation and activation of osteoclasts. This would go in line with recently 
published reports that showed a correlation between diet dependent plasma hcys 
levels and bone mineral density (82), with the correlation found between plasma hcys 
levels and collagen cross-link ratio in forming trabecular surfaces in humans (72) and 
with recently published clinical and epidemiological articles which demonstrated a 
correlation between blood hcys levels and bone fracture risk (72-74). The results and 
mechanisms presented in this thesis and the here mentioned publications emphasize 
the complex role of hcys for bone health and metabolism. Thereby the long-term 
effect of this metabolic compound on bone homeostasis may depend on several 
factors like the local environment, nutrition, genetic predisposition, serum 
concentrations and others. Thus, targeted dietary approaches designed to counteract 
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high hcys serum levels may be useful to alleviate or minimize the negative effects of 
hcys on bone. However, in order to understand the implications and the effects of 
such approaches, further large-scale studies are needed. Nevertheless, first small 
scale studies showed that nutritional habits influence epigenetic DNA methylation 
thus modulating specific gene promoter methylation. Thus, it was published that 
compared to omnivores, consumers of a vegetarian diet express higher levels of the 
enzyme super oxide dismutase 2 (SOD2) which acts as radical scavenger in 
mitochondria. This difference was linked to a higher SOD2 promoter methylation in 
omnivores when compared to consumers of a vegetarian diet. The results were 
suggested to rely on the different vitamin B12 intake between the two groups (127).  
In regard to Lox promoter methylation by hcys, we show for the first time that beside 
the role of hcys in DNA methylation cycle, via a complex signaling pathway this 
compound directly modulates the expression of the genes involved in DNA 
methylation. Interestingly, hcys up-regulated the expression of Dnmt1, Dnmt3b and 
of Hells leaving the expression of Dnmt3a unaffected. HELLS was recently reported 
to act as DNA methylation supporter by recruiting DNMT1 and DNMT3B to the 
promoter (85). Furthermore, Hells was shown to play an essential role in bone 
development as Hells knock down mice show a clear, pathological bone phenotype 
including osteoporosis, osteopenia, delay in bone development, decreased bone 
mineral density and smaller epiphyses (128). Recently we observed that DMSO 
down regulates the expression of Dnmt1, Dnmt3b and Hells. However, as 
demonstrated here, DMSO also failed to regulate Dnmt3a (personal observations). 
Therefore, in addition to the synchronized activity of DNMT1, DNMT3B and HELLS at 
the protein level, we suggest a common mechanism regulating the mRNA 
expressions of these three genes, which may exclude regulation of Dnmt3a mRNA 
expression.  
In contrast to other cells and tissues, to date little research has been performed 
concerning epigenetic gene regulation in bone development and pathogenesis. Lox 
expression was shown to be regulated by epigenetic DNA methylation in humans 
(129-131) and mice (110). Besides LOX role in collagen cross-linking, the N-terminal 
peptide of this enzyme acts as tumor-suppressor. In tumors, Lox expression is 
prevented by CpG-methylation of the promoter. Thus, our findings add new 
mechanistic insights to hcys’ role as a risk factor for bone health. 
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In the experiments described in this thesis, we decided to treat the pre-osteoblastic 
MC3T3-E1 cells with pharmacological hcys doses which are even abundantly higher 
than mean pathological serum levels in humans. It is well known that pathologies 
related to high hcys serum levels rely on chronically high serum levels of this 
compound. Therefore, to increase the possibility to detect effects, to reduce 
treatment time and thus making experiments suitable for cell culture conditions we 
selected the hcys concentrations showed in the results. Furthermore, in vivo on 
tissue or even on cellular level, it cannot be excluded that local hcys 
accumulations/concentrations are much higher than the measured hcys serum 
concentrations.  
As we have shown here, lathyrogens like bAPN and hcys modulate ECM formation 
hindering collagen cross-link formation. Furthermore, by gene array analysis we have 
shown that hcys down-regulates the mRNA expression of several genes implicated in 
intra and extracellular post-translational collagen folding and assembling. Very recent 
works provide first insights in the role of collagen folding for ECM to cell signaling. 
Aberrant collagen triple helix assembling which results in a partially denatured 
collagen triple-helix, exposes specific binding sites which are hypothesized via 
specific cell adhesion receptors to regulate cellular behavior during tissue repair and 
regeneration (11). It was shown that osteoblasts adhering to partially denatured type 
I collagen behave differently as osteoblasts seeded on plates coated with correctly 
folded type I collagen. Thus, the mRNA expression of osteoblastic genes like Runx2 
or bone sialo-protein as well as the extracellular calcium deposition was significantly 
higher in cells attaching on native collagen then on partially denatured collagen (21). 
The here described effects of hcys on the mRNA expression of collagen-folding 
enzymes let presume that beside the attenuated collagen cross-link formation, 
efficient collagen triple helix folding is also hindered under elevated hcys 
concentrations. However, interpreting the literature regarding this issue (21), this 
would be in contrast with the observed effect of enhancement of osteoblastic 
differentiation by hcys. As described above, hcys affects several cellular pathways 
(as for example the IL-6/JAK2/Stat pathway) and mechanisms. Thus, the feedback 
signals rising from a hcys-marred ECM may be decoupled and/or subordinate to the 
hcys activated Il-6/JAK2/STAT signaling pathway which is known to trigger cell 
differentiation. This aspect may represent a further pathological aspect for bone in 
regard to high hcys levels: triggering of osteoblastic differentiation with concomitant 
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degeneration/malformation of bone ECM. However, effects of hcys on fibrillogenesis 
during ECM formation as well as the specific osteoblastic response on the diverse 
pathological bone matrix are still open issues.  
ECM to cell interactions control important cellular events. Adhesion of osteoblasts to 
ECM not only guarantees structural anchorage of the cells but also mediates primary 
signals to the cells (6, 11, 21, 22). It is well known that interaction of cells with an 
adequate ECM prevents from anoikis (homelessness, a specific form of apoptosis) 
and triggers cell differentiation. The involvement of the pro-apoptotic gene Fas in 
anoikis is well documented (132); however, until recently the mechanism behind was 
still unclear. Fas, a member of the TNF-receptor super family, plays an essential role 
in the initiation of programmed cell death (110, 132). In this work we demonstrated 
for the first time that the main organic bone ECM-component, namely collagen type I, 
up-regulates the expression of genes involved in differentiation and cell cycle 
regulation and down regulates Fas in MC3T3-E1 mouse osteoblasts (107). Recently, 
Dnmt1 was shown to play central role in maintenance of Fas promoter methylation 
(110) and findings presented in this thesis concerning ECM up regulation of Dnmt1, 
suggested an epigenetic mechanism for attenuation of Fas expression. This was 
confirmed by methylation analysis of the Fas-promoter, where it could be 
demonstrated increased methylation of a CpG rich region (107). 
Additionally to repression of Fas, collagen type I dependent up-regulation of Cyclin 
A2 mRNA expression was found as well. Increase of Cyclin A2 expression was 
recently demonstrated to be epigenetically regulated via CpG methylation. Unlike the 
common repressive effect of promoter CpG methylation on gene expression, in the 
case of Cyclin A2 it was shown that methylation of two specific CpG sites located at 
two repressor binding sites on Cyclin A2 promoter hinder binding of the repressor 
factors thus increasing Cyclin A2 expression (89). Therefore, assuming epigenetic 
methylation for collagen mediated up-regulation of Cyclin A2 expression, we 
compared Cyclin A2 promoter methylation in collagen seeded to plastic seeded 
MC3T3-E1 cells. However, in this case there was no associated methylation of those 
CpG sites which should repress Cyclin A2 mRNA expression (data not shown).  
We found that the collagen mediated methylation of Fas promoter by Dnmt1 was 
FAK, MAPK and AP-1 transcription factor dependent. Depletion of the collagen 
effects in cell culture was achieved by using natural food compounds like genistein 
and resveratrol, which represent the main flavonoid present in soy and a phytoalexin 
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present in red grapes, respectively. For genistein, resveratrol and other nutritional 
factors as well as for nutritional habits, interference with epigenetic regulation of gene 
expression was demonstrated before (127, 133-135). For example, it was shown that 
maternal genistein protects agouti mice offspring from obesity by modifying the 
promoter CpG methylation status of the agouti gene (134). Further, it was shown that 
vegetarians show a higher SOD2 expression in buccal swab cells when compared to 
omnivores due to a lower CpG promoter methylation of this gene (127).  
The influence of environmental factors including nutrition habits and food compounds 
on epigenetic regulation of gene expression, become more and more important 
topics in medical research. The elucidation of possible associations between the 
environment and modulation of gene expressions as well as of the development of 
diseases like cancer, diabetes, adipositas and others, is a main target of the actual 
research efforts. The presented data on epigenetic effects of natural food compounds 
on collagen mediated osteoblastic cell multiplication, differentiation and function allow 
speculations that nutritional factors may influence bone development and 
homeostasis by the involvement of epigenetic mechanisms. Furthermore, an 
adequate environment for osteoblasts, which guarantees correct ECM synthesis and 
assembly, may be of particular importance for a physiological bone development.  
In summary, results presented in this thesis revealed a new epigenetic mechanism 
which may play an important role for osteoblasts in avoiding anoikis by adhesion to 
an adequate ECM. Furthermore, the stimulation of the expression of markers of 
osteoblastic proliferation and differentiation underlines cell fate decisions directed by 
collagen. Furthermore, hcys influences not only collagen cross-linking by inhibition 
LOX enzymatic activity, it itself down regulates Lox expression by epigenetic DNA 
CpG methylation. This increased methylation is mediated by increased expression of 
Dnmt1, which is regulated by Fli1 that is stimulated via JAK2 by IL-6. IL-6 itself is a 
pleiotropic factor, which also influences osteoclastic development and function.  
In conclusion, the work presented in this thesis add important information on the 
action of nutritional components and endogenous metabolites on bone metabolism 
and how these components can influence bone quality and with it the quality of life.  
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